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Malaria is one of the three prime causes (together with tuberculosis and AIDS) 
responsible for the high mortality in this world. 300-500 Millions people suffer from the 
disease every year resulting in about one million deaths. In recent years, malaria is 
considered as a complex multisystem disorder. As more than 40% of the world’s 
population lives in malaria endemic areas, the challenge is to understand the complexities 
of this disease and develop potential tools for improving the present scenario. There is 
also the immediate need for the discovery of cost effective drugs or vaccines to fight 
mainly chloroquine-resistant strains of P. falciparum. 
The lipopeptide (N1708) isolated from Streptomyces sp. using bioassay-guided 
isolation by MerLion Pharmaceuticals exhibits promising activity against Plasmodium 
falciparum (IC50= 0.8 µM against 3D7 strain). NMR and mass analyses suggest that this 
peptide contains two non-proteinogenic amino acids, one aspartic acid and a ten carbon 
long chain fatty acid containing a trans-double bond and a chiral centre. As it is a well-
known problem that the half life of peptide drugs is short because of the enzymatic 
hydrolysis of the amide bond formed by proteinogenic amino acids, thereby we are 
interested to find out the configuration of these six chiral centres (one of them is 
quaternary) present in this lipopeptide. Synthesis and stereochemical assignment of the 
non-proteinogenic amino acids and rest of the fragments have been performed in this 
work. The non-proteinogenic amino acids have been synthesised and their absolute 
configuration assigned to the chiral centres with the help of Marfey’s reagent. The full 
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1.1      Malaria background 
Malaria is one of the three prime causes (together with tuberculosis and AIDS) 
responsible for high mortality in this world. 300-500 Millions people suffer from the 
disease every year resulting in about one million deaths.1 It is a very old parasitic 
disease caused by different types of Plasmodium species namely P. falciparum, P. 
vivax, P. malariae and P. ovale. P. falciparum is the most deadly one for the majority 
of humans. High fever, chills, headache and vomiting are the signs of malaria. Severe 
malaria is traditionally viewed in two pathogenic processes; destruction of red blood 
cells (anaemia) and cerebral malaria (CM) due to small vessels blockage in the brain 
by sequestered parasites. In recent years, malaria is considered as a complex 
multisystem disorder.2 As more than 40% of the world’s population lives in malaria 
endemic areas (Figure 1.1), the challenge is to understand the complexities of this 
disease and to produce some potential tools for improving the present scenario. There 
is also the immediate need for the discovery of cost effective drugs or vaccines to 







Figure 1.1: Global malaria distribution and endemicity, 2003.* 
 
 
1.1.1 Life cycle of the malaria parasite 
The life cycle of malarial parasites (Figure 1.2) is distinctly divided into two 
hosts. The female anopheles mosquito, where the sexual cycle of the parasites takes 
place, is the primary host. The secondary host is the human body, which is needed for 
completing their asexual cycle. Sporozoites are released into the human blood stream 
when an infected female anopheles mosquito bites. Sporozoites first hit the human 
liver and begin their asexual cycle resulting in the formation of merozoites which 
enter the erythrocytes and grow as trophozoites in the ring stage by feeding on the 
host cell haemoglobin. Lysis of the erythrocyte releases merozoites that attack new 
erythrocytes thus completing the cycle. This whole process occurs in 48 hours and the 
release of merozoits from red blood cells (RBC) causes the sporadic symptoms of 
fever, shivering and anaemia, i.e., the characteristics of malaria. During this process, 
some immature trophozoites produce gametocytes. The male and female gametocytes 
enter into the mosquito when it bites the person carrying the parasite. After reaching 
the mid-gut of the mosquito, female gametocytes transform into macro-gametes 
whereas the male gametocytes divide into micro-gametes. Next, the male and female 





various complex stages. Finally sporozoites reach the salivary glands and are 




Figure 1.2: Life cycle of Plasmodium falciparum.20 
 
 
1.1.2 Haemoglobin metabolism 
Metabolism of haemoglobin is crucial for the survival of the malaria parasite.3 
Inside the erythrocyte the parasite breaks down the host haemoglobin to produce 
amino acids for parasitic protein synthesis.4,5,6 Aspartic protease (plasmepsin) initiates 
the break down process and then cysteine protease (falcipain) and some other 
proteases are involved for proteolysis to occur optimally in the acidic food vacuole 
(FV). Here, it is found that plasmepsins (PM) are highly selective towards native 





phenylalanine and 34-leucine which is vital for the tetrameric structure of 
haemoglobin. Cysteine protease is unable to detect the native haemoglobin, but it 
takes part to degrade denatured haemoglobin.7  The aspartic protease can also cleave 
the 105-106 peptide bond in the loosely folded α chain, but not in native 
haemoglobin.8,9 The metalloprotease falcilysin can only hydrolyse small peptides.10 
Dipeptidyl aminopeptidase 1 (DPAP1) is known to be involved to the hydrolysis of 
haemoglobin derived oligopeptides.11  Finally, free amino acids are produced in the 
cytoplasm by aminopeptidases.12 The general pathway is depicted in Figure 1.3.13 
Degradation of haemoglobin produce considerable amounts of heme which is almost 
entirely oxidised from ferrous (II) to ferric (III) hematin.14 As heme and hematin are 
toxic to the parasite, the released hematin is detoxified by polymerase activity to 
generate the crystalline insoluble polymer hemozoin.15 Hemozoin is also well known 










1.2      Antimalarial drugs 
As the mechanisms of action of most antimalarial drugs are not clear, one 
popular way to categorise them is according to their activity in different stages of 
parasite life cycle. 
1.2.1 Causal prophylaxis 
These type of agents have lethal effects at the pre-erythrocytic stage of the 
parasite. Primaquine and malarone are currently used for that purpose. As these work 
at an early stage, this agents prevent the typical characteristics of malaria. Vaccines 
can be a very effective tool in this category in future.16 
1.2.2 Suppressive  prophylaxis 
Suppressive treatments work at the erythrocytic stage. Causal prophylactic 
agents along with those used for chemoprophylaxis are applied when travelling in 
malaria endemic areas. Common suppressive prophylactic agents are chloroquine and 
mefloquine. 
1.2.3 Clinical cure 
These type of agents are involved in killing erytrocytic schizogony and prevent 
clinical attack. They are also called blood schizonticides. These include the 4-
aminoquinolines (e.g. chloroquine), the phenanthrenes (e.g. halofrantrine), the 
antifolates (e.g. pyrimethamine, proguanil, dapsone and sulfadoxine), the artemisinin 
group (e.g. dihydroartemisinin, artesunate and artemether) and some antibiotics (e.g. 
tetracycline and doxycycline). 
1.2.4 Radical cure 
After elimination of the parasite from the bloodstream, the hypnozoites are 





1.2.5 Controlling transmission 
Transmission of malaria via mosquito can be restricted by demolishing the 
gametocytes using primaquine, the artemisinins and pyrimethamine. 
 
 
Figure 1.4: Structurally different antimalarial drugs. 
 





1.2.6 Quinoline with secondary alcohols 
Quinine and mefloquine belongs to this group. Quinine was isolated from the 
bark of cinchona trees whereas mefloquine (a synthetic analogue of quinine) was 
developed by the Walter Reed Army Institute of Research in 1970. Quinine was the 
only known effective drug for many years for the treatment of malaria but currently it 
is only used for the treatment of severe malaria due to increasing drug resistance. 
Although the exact modes of action of these drugs are not known, it is believed that 
they play a role in preventing hemezoin formation from heme.18 
1.2.7 8-aminoquinilines 
Primaquine (1-3) is the only marketed antimalarial drug that belongs to this 
group. This is a radical cure agent. Tafenoquine shows promise in a clinical trial 
(phase II) for the treatment of P. vivax in adults. The main advantage of tafenoquine is 
its long half-life and thereby no need to take as frequently as primaquine.19 It is 
proposed that this class of drug has an effect on parasite mitochondria. 
1.2.8 4-aminoquinilines 
Chloroquine (1-4) is the main drug that belongs to this group. This highly toxic 
compound was considered as an antimalarial drug during the Second World War. It 
was the first-line treatment even ten years ago but huge parasite resistance has forced 
a reduction in its use. This class may also have an important role in the heme 
poisoning process. 
1.2.9 Antifolates 
This class of antimalarials works by inhibiting dihydrofolate reductase (DHFR) 
and deoxyhypusine synthase (DHPS). Pyrimethamine (1-5) and proguanil (1-6) are 





sulfones) are DHPS inhibitors. Sulfadoxine and pyrimethamine are used in 
combination for drug therapy in some parts of Africa.18 
1.2.10 Antibiotics 
Antibiotics are used along with other antimalarial drugs. Tetracycline and 
doxycycline are the common drugs for this purpose. 
1.2.11 Phenanthrenes 
Halofantrine (1-11) is a popular antimalarial drug in this class. This was 
identified during the Second World War. This class of drug acts on blood schizonts in 
preventing the disease. 
 







Artemisinin is a very useful antimalarial. Because of poor bioavailability, the 
semi-synthetic artemether (1-12a) and artesunate (1-12b) were developed. The 
artemisinin class of drugs has a unique radical mode of action (Figure 1.5)20 therefore 
drug resistance is not found significantly. However it has been reported in 2008 that 
some resistance is developing in western Cambodia.21 This group of drugs are the last-




















1.3      Antimalarial drug resistance 
The main challenge for fighting against malaria is its emerging parasite 
resistance to almost all the marketed drugs to date.22 In addition, multidrug-resistance 
strains of P. falciparum has been identified in many parts of the globe.23 In most of the 
cases, the resistance comes from mutations in genes encoding the parasite drug target 
or influx/efflux pump that is crucial for maintaining the drug concentration at the 
target. The mechanism of chloroquine resistance has been studied in detail and its 
resistance in P. falciparum may be multigenic but is largely recognised to occur by 
mutations in genes encoding transport membrane proteins of the digestive vacuole.24 
To circumvent this problem, it is important to develop drugs with different modes of 
action. Presently, several combination therapies have been taken as a strategy so that 





combination therapies are in developmental stage and some has been approved for 
clinical use.26   
1.4      Antimalarial drug targets 
As emerging drug resistance is a challenging problem for the treatment of 
malaria, many new approaches have been proposed. Identification of novel drug 
targets and design of new molecules for the known targets is one of the major research 
area developed in present scenario,27 especially after releasing the genome sequence 
of P. falciparum.28 Currently these targets can be categorised as: 
 a) Targets responsible for membrane transport and signalling (e.g. protein kinases 
and the choline transporter). 
 b) Enzymes involved in macromolecular and metabolite synthesis (e.g. DOXP 
reductoisomerase, parasite HGXPRT and lactate dehydrogenase). 
 c) Targets taking part in the processes occurring in the digestive vacuole (e.g. 
haemoglobin digestion and haem detoxification). Proteases namely plasmepsins and 
falcipans are the most explored in this class of targets.29 
1.4.1 Protein kinases 
Protein kinases (PKs) encoding genes in the P. falciparum genome have been 
characterised recently.30 This study has highlighted that a classical gene identification 
approach is not suitable for plasmodium functional gene identification. However a 
reverse genetic approach has been used to address this issue. Protein kinases are 
believed to be involved in signal transduction processes essential for parasite growth. 
It has been found that PKs of Plasmodium and mammalian are different in their 
compositions and organisation of signalling pathways.31 PfCPK and PfCPK2, the 





this class of enzymes has been isolated only in plants and some protozoan species. 
This makes the target promising as it may be significantly different from mammalian 
PKs. 
1.4.2 Choline transporter 
The malaria parasites protect themselves from the host immune system by 
invading RBCs. This is important for developing antimalarials because drugs must 
pass through multiple membranes (the red cell membrane, the parasitophorous 
vacuolar membrane, the parasite plasma membrane, the food vacuole membrane and 
the mitochondrial membrane) to access most intra-parasitic targets, depending on the 
site of action of the drug. It is known that malaria-infected human RBCs have better 
permeability than normal RBCs and show a new permeation pathway (NPP).33 NPP 
may consist of single or multiple channels, which prefer anions over cations. Choline 
carrier activity is much (10 fold) higher in infected RBCs. The antimalarial activity of 
choline analogues is due the inhibition of the de novo synthesis of major parasite 
phospholipid phosphatidylcholine (PC) which is essential for supplying large amount 
of phospholipid in infected RBCs.34 It is also assumed that the parasite plasma 
membrane (PPM) choline transporter has a significant role for killing parasite using 
the choline mimic compounds.35 As infected RBCs are very much different from 
normal RBCs, the choline transporter becomes an interesting target for developing 
antimalrials. 
1.4.3 DOXP reductoisomerase 
1-Deoxy-D-xylulose-5-phosphate (DOXP) pathway was found as an 
alternative nonmevalonate pathway for the biosynthesis of isoprenoids in some 





condensation gives DOXP, which is finally converted to 2-C-methyl-D-erythritol-4-
phosphate by the enzyme DOXP reductoisomerase. The similarity of DOXP 
reductoisomerase found in P. falciparum suggests the existence of a nonmevalonate 
pathway. As this alternative pathway is absent in humans, scientists are interested in 
this parasite specific enzyme as a future target to combat malaria.36  
1.4.4 Purine salvage enzyme HGXPRT  
Malaria parasites in the intra-erythrocytic stage are unable to synthesise purine, 
thereby needing to rely on pre-formed host purine precursors. Parasites use the 
salvage enzyme hypoxanthine-guanine-xanthine phosphoribosyltranferase (HGXPRT) 
for converting purine bases (from the host) to nucleotides needed for their DNA and 
RNA synthesis. So, if we introduce some purine base analogues, then HGXPRT will 
use them to produce nucleotide which will be toxic to the parasite. One major issue in 
this strategy is that, this type of purine analogues should be very specific for parasite 
enzyme not for similar type of human enzyme HGPRT. The chlorine or nitrogen 
position in the purine analogues has a significant role for their specificity towards the 
parasite enzyme over the human enzyme. This encouraging result validates the 
parasite HGXPRT as a potential drug target for developing animalarials.37  
1.4.5 Lactate dehydrogenase 
Malaria parasites have to depend on glycolysis primarily for producing energy 
for themselves. It is known that the NAD+ used up during glycolysis process is 
generated back by the fermentation of pyruvate in the cytoplasm and/or through the 
electron transport process occurring in the mitochondria. Unlike the mammalian cells, 
pyruvate does not enter the citric acid cycle (TCA) in plasmodia. Pyruvate is reduced 





pyruvate is not an inhibitor of LDH, the energy production is fast which helps the 
rapid growth of the parasite. Plasmodial LDH is different from its human counterpart 
by the presence of a 5 amino acid insertion at the pyruvate binding site. This specific 
divergent can be explored as a potential drug target.29 
1.4.6 Plasmepsins 
The aspartic proteases in plasmodium are called plasmepsin (PM). Ten 
plasmepsins (PM I, II, IV, V, VI, VII, VIII, IX, X and histo-aspartic protease) are well 
known plasmepsins found in plasmodium parasite.13 The exact contribution of each 
PM is not clear to date but PM I, II, IV, V, IX and X are involved in the erythrocytic 
stage whereas PM VI, VII and VIII are expressed in the exo-erythrocytic stage. It is 
known that PM I and II are found to be involved significantly in haemoglobin 
metabolism. Haemoglobin metabolism takes place only in an infected RBC. This 
specific event makes PM I and II very popular drug targets for antimalarials. Recently 
the PM IV and the histo-aspartic protease (HAP) have been found to be localized in 
the parasite food vacuole and shown to participate in haemoglobin digestion.9 In 
addition to haemoglobin catabolism, PM II and IV are also known to be involved in 
rupturing the host erytrocytic membrane.38 The main hurdle is to develop the drug, 
which is specific to the plasmepsin and not to the similar counterpart human aspartic 
protease cathepsin D (Cat D). 
1.4.7 Falcipains 
The well known cysteine proteases of P. falciparum are called falcipains (FP). 
A cysteine-histidine pair that is embedded at the catalytic centre is key to their 
catalytic activity. The FP-2 and FP-3 are known to be located in the food vacuole and 





whereas FP-2 is also involved in the cleavage of erythrocyte membrane skeletal 
proteins, including ankyrin and protein 4.1 at the late trophozoite and schizont stages. 
This proteolysis of the skeleton protein causes RBCs instability thereby releasing the 
parasite.39 The crystal structure of the free FP-2 and in complex with cystatin are 
known.40 More recently, the crystal structures of FP-3 in complex with leupeptin have 
been reported.41 These structural details of  FP may help to design drugs in the future. 
1.5      Antimalarial peptides 
Several peptides are found to be active against the malaria parasite. A few very 
































  Ki PM II, 0.56 nM, Ki Cat D, 21 nM42                       Ki PM I, 0.39 nM, Ki PM II, 0.025 nM,9  
                                                                                    Ki Cat D, 0.0038 nM43, P. falciparum IC50, 4 µM44 
      
Ki PM II, 50 nM, Ki Cat D, 320 nM45                  Ki PM I, 4.1 nM , Ki PM II, 95 nM, Ki Cat D, 180 nM46 
 
Ki PM I, 2.7 nM , Ki PM II, 0.25 nM, Ki Cat D, 340 nM47 
 





1.6      Aims of this study 
The lipopeptide (N1708) isolated from Streptomyces sp. using bioassay guided 
isolation by MerLion Pharmaceuticals exhibits promising activity against Plasmodium 
falciparum (IC50= 0.8 µM against 3D7 strain). NMR and mass analysis suggests that 
this peptide contains two non-proteinogenic amino acids, one aspartic acid and a ten 
carbon long chain fatty acid with a trans double bond and a chiral centre. Merlion 
Pharmaceuticals proposed the linear structure and found that this peptide was already 
patented48 as an antimalarial agent that is interestingly not active against mammalian, 
fungi and Gram positive bacteria cell lines. As it is a well known problem that the half 
life of the peptide drug is short because of the enzymatic hydrolysis of the amide bond 
formed by proteinogenic amino acids thereby we were interested to find out the full 
structure of this lipopeptide. Synthesis and stereochemical assignment of the non-
proteinogenic amino acids and the rest of the fragments was performed in this work. 
Full structure determination has also been confirmed by the total synthesis of the 
complete lipopeptide.  
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Hydrolysis of the Peptide and Identification of Amino Acids 
2.1      Hydrolysis of peptide N1708 
We first hydrolysed the isolated natural peptide by refluxing with 6M HCl for 
24 hours. This acidic reaction mixture was extracted with chloroform to obtain the 
fatty acid fragments (amino acids should remain in the water layer because of the 
amine salt formed in the acidic medium). This fraction was injected into the GCMS 
but we were unable to detect the fatty acid. We believed that during the hydrolytic 
process, the double bond of the fatty acid part reacted and formed some volatile 
residue. Next, we took a small part of the water layer and treated this with Marfey’s 
reagent (ref. [16] in chapter 3) to prepare the Marfey’s derivative of each amino acid 
residue for comparison purposes. The main water part was treated with benzyl 
chloroformate (CbzCl) to protect all the amine groups present in the amino acids. We 
chose Cbz because of its UV activity would help us separate each derivatised amino 
acid fragment by preparative HPLC. After isolation of each Cbz protected amino acid 
fragment, we ran their NMR to reconfirm the structure of the amino acid fragments. 
Aspartic acid 1 and disubstituted aspartic acid 3 were the same as expected. 
Interestingly, 1H-NMR did not match with the Cbz protected isoleucine derivative 
residue 2. The expected double bond peak was missing and two singlets were 
observed instead of one. The corresponding peak of the double bond was also missing 





quaternary centre) was observed. Interestingly, the ESI mass showed exactly the same 
mass as expected, although the NMR were dissimilar. 
 
Figure 2.1: Linear structure and fragments of the isolated natural lipopetide N1708. 
 
 
Figure 2.2: Prep HPLC chromatogram of Cbz protected amino acids from peptide 
N1708. 
 
Preparative conditions:  
Solvent A: (H2O+0.1%HCOOH) 
Solvent B: (ACN+0.1% HCOOH) 
Flow rate: 15mL/minute  
Column: XTerra® Prep RP18  OBD TM Column, 5µm, 19х 30mm 
 
Analysis programme: 
Time (minute) 0  3 10 40 








These observations suggested that the double bond was converted to 
something which had the same mass. We proposed a 5-membered lactone. We 
reasoned that during the hydrolysis process double bond was protonated and generate 
a stable tertiary carbocation, which was trapped intramolecularly by the carboxylic 
acid group to form the lactone. To clarify this, we isolated the lactone (with free 
amine) from the acidic water layer. We thus hydrolysed the natural peptide again on a 
small scale. The acidic layer was basified by NaHCO3 (to make the sodium salt of the 
free carboxylic acid so that all the other amino acids would dissolve in water) and then 
extracted with chloroform to obtain the lactone with the free amine. Indeed, the 
lactone (2-2) was confirmed by NMR and mass analysis. After confirming the lactone 
structure, we thought this cyclic structure would help us predict the relative 
stereochemistry of α and β carbon centres. The coupling constant was 12 Hz in the 
isolated lactone, which indicated a trans relative stereochemistry in the lactone. This 
relative stereochemistry was again supported by nOe experiments. Finally, it was 





























2.2      Stereochemical assignment of the aspartic acid residue 
Marfey’s reagent (FDAA) was used to derivatise the pure aspartic acid (L- and 
D- forms) and the whole amino acid mixture obtained from peptide hydrolysis. 
Because of one fixed chiral centre present in Marfey’s reagent, it produced a 
diastereomer after being coupled with the amino acid. Next, we injected all the three 
reaction mixtures into the LCMS and found the retention time of L-aspartic acid 
derivative matched with the natural amino acid residue. We thus concluded that the 
aspartic acid present in the peptide was L (S configuration). 
 























2.3     Conclusion 
In this chapter, we reconfirmed the structure of the amino acid fragments. The 
relative stereochemistry of the isoleucine derivative 2 was identified. The absolute 
stereochemistry of aspartic acid 1 was confirmed by Marfey’s reagent. We will 
discuss in the following chapter how we synthesised and confirmed the absolute 










Synthesis of 2-Amino-3, 4-Dimethylpent-4-Enoic Acid 
3.1      Direct methylation of aspartic acid 
Having identified the linear structure of lipopeptide N1708 and amino acid 
fragments, it was necessary to make a general protocol to produce the isomers of 2-
amino-3,4-dimethylpent-4-enoic acid 3-7a for determining the absolute configuration 
of the two chiral centers present in this fragment. We planned to use aspartic acid 
because generation of another chiral centre with the methyl group would give 
diastereomers (Scheme 3.1). The β-carboxylic acid of aspartic acid was selectively1 
converted to its methyl ester with dry HCl. Monoester salt 3-2 was protected with 






















































The free acid group was reacted with tBuOH in the presence of DCC and 
DMAP in DCM to produce the corresponding tert-butyl ester 3-4.2  We converted two 
carboxylic groups with two different ester groups because according our plan we 
needed to convert β-carboxylic acid to the Weinreb amide. Unfortunately, we faced 
many problems to install the methyl group at the β-centre. Different reaction 
conditions3 were used as shown in Table 3.1. 
 
Table 3.1: β-Methylation studies of protected aspartic acid. *Isolated yield. 
 
 
At this point, we thought that changing the ester and the amine protecting 
group might help with the methylation yield. The carboxylic group of 3-3 was thus 
converted to the benzyl ester.4 Alternatively, the carboxylic and the amine group of 3-
2 were converted to its tert-butylester and Cbz derivative, respectively.5 Several 
reaction conditions6 were tried to improve the yield of the β-methylated product, but 
all the attempts were unsuccessful in our hands (Table 3.2).   
 
Entry Reagents Conditions Results* 
3-4 3-5a 3-5b 
1 NaHMDS (2.2 eq), 
MeI 
-78 oC  to -10 oC, 1 h 
-78 oC  to -30 oC, 2 h 
0% 0% 0% 
2 LiHMDS (1.1 eq), 
BuLi (1.2 eq.), MeI 
-78 oC  to 0 oC, 0.5 h 
-78 oC  to rt, 16 h 
10% 15% 7% 
3 LDA (2.2), MeI -78 oC to -30 oC, 1 h 
-78 oC to rt, 20 h 

















1. K2CO3, CbzCl MeO2C
CO2tBu
NHCbz
42% (Over two steps)3-2 3-10


































Entry Reagents Conditions Results* 
3-8 3-9a 3-9b 
1 LiHMDS (2.2 
eq), MeI 
-78 oC to -30 oC, 1 h 
-78 oC to rt, 12 h 
70% 0% 0% 
2 NaHMDS (2.2 
eq), MeI 
-78 oC to -30 oC, 1 h 
-78 oC to rt, 12 h 
0% 0% 0% 
   3-10 3-11a 3-11b 
3 LiHMDS (2.2 
eq), MeI, LiCl 
-78 oC to -40 oC, 2 h 
-78 oC to rt, 14 h 
85% 0% 0% 
4 BuLi (1.2 eq), 
NaHMDS (1.1 
eq), MeI 
-78 oC to -40 oC, 2 h 
-78 oC to rt, 14 h 





3.2      Synthetic plan via 1, 3-oxazin-6-ones  
After being unsuccessful at a direct methylation, we changed our plan and 
sought to follow a 2nd generation reaction sequence (Scheme 3.3). We found a 
different procedure developed by Young et al. to install the methyl group at the α 
position of the terahydro-1,3-oxazin-6-ones.7 For this purpose, the methyl ester of 3-4 
was converted to carboxylic acid 3-12, which was treated with paraformaldehyde in 
acidic condition to form the terahydro-1,3-oxazin-6-one 3-13. Bredereck’s reagent 
was used to form the β-N,N-dimethyl α,β-unsaturated lactone, which was reduced to 
produce the methylated 1,3-oxazin-6-ones 3-15a and 3-15b. It is believed that the enol 
3-18 formed from 1,3-oxazin-6-ones reacted with amidinium ion to form 3-19 and 
then an elimination process took place to generate 3-20. In the next steps, reduction 
followed by elimination produced the exomethelene group, which upon reduction by 
catalytic hydrogenation afforded the methylated product. Two diastereomers can be 
separated by careful column chromatography in moderate yield. One of them was 
confirmed by X-ray crystallography. We faced a problem to cleave the N,O-acetal 
type bonds to produce 3-16. It was found that the reaction was sluggish in acetic acid-
water medium at 45 oC. We managed to afford trace amount of 3-16 in poor yield (4%) 
and decided to abort this scheme at this stage because Bredereck’s reagent was costly 




















































































       





































Scheme 3.3: 2nd Generation synthetic plan of isoleucine derivative (3-7). 
 





3.3      Synthetic plan with threonine  
After another unsuccessful result to install the methyl group, we sought to start 
our synthesis with the methyl group already present in the molecule. With this vision 
in mind, we moved to a 3rd generation plan. Here, the acid group of the natural 
threonine was protected as its benzyl ester8 and the amine with Cbz. The secondary 
alcohol 3-22 was converted to its mesylate so that it could be displaced by the cyanide 








35% in two steps
DIPEA, MsCl



















Scheme 3.4: 3rd Generation synthetic plan of isoleucine derivative (3-7b). 
 
 
Our attempts to convert the cyano group to an acid or equivalent group (amide 
or ester) ultimately failed. We investigated a variety of acidic conditions to hydrolyse 
the cyano group. Sodium hydroxide in the presence of hydrogen peroxide was used to 
make strong nuceophilic conditions to form the acid. Strong acidic medium in MeOH 
at elevated temperature also failed to produce the methyl ester. Next, the cyano 
compound was refluxed with Hg(OAc)2 in AcOH to obtain the amide.9 This effort 
also failed (Table 3.3). We did not attempt harsher basic conditions to avoid potential 





next to the cyano group might cause some steric repulsion so that neucleophiles were 






















Next, we realized that instead of going through the Weinreb amide we might 
get our desired 3-methyl-4-keto ester (e.g. 3-28) using dithiane chemistry. For this 
purpose, the methyl substituted dithiane nucleophile was generated with BuLi and 
then the mesylate was added to the reaction mixture at low temperature to accomplish 
the desired 3-27. Unfortunately, these attempts failed. On the other hand, it was 
planned to synthesise 3-29 using nitroethane, keeping in mind that later we could 
convert the nitro group to a ketone 3-28 using Nef conditions. This attempt was also 
unsuccessful. As the steric effect created by the adjacent methyl group might be the 
cause for the failure of these reactions, we wanted to introduce an alkynyl (by 
displacing the mesylate group with Grignard reagent in presence of CuI) since the sp 
hybridized carbon nucleophile would be linear thereby reducing steric effects. This 
group could then be converted to the ketone using oxymercuration-demercuration 
Entry Reagents Conditions Results (R1) 
1 60% aq. H2SO4 60 oC, 10 h CO2H 
2 3N NaOH, 30% H2O2 70 oC to 90 oC (2 h) CO2H 
3 Conc. HCl Reflux, 10 h CO2H 
4 H2SO4, MeOH Reflux, 10 h CO2Me 
5 Hg(OAc)2, AcOH Reflux, 10 h CONH2 





reaction conditions. This strategy also did not work in practice and produced 




Scheme 3.5: Attempts to replace -OMs with different nucleophiles. 
  
 
3.4      Proline catalysed Mannich reaction  
After several unsuccessful studies we concentrated on the L-proline catalysed 
asymmetric Mannich reaction developed by Barbas III.10 We thus planned to prepare 
the syn amino acid fragment 3-33 using both D- and L- proline. This plan was 











Scheme 3.6: 4th Generation synthesis of the isoleucine derivative (3-36). 
 
 
Imine 3-32 was prepared following the literature procedure11 and was then 
reacted with ketone 3-31 to produce 3-33 in 99% ee. Various Wittig reaction 
conditions were tried to convert the ketone to the methelene, but all were unsuccessful 
presumably due to the steric effect created by the α-methyl group in this highly 
functionalised small molecule (Table 3.4). Finally, we prepared 3-34 by chemo-
selective olefination of ketone 3-33 in presence of ester by employing Tebbe reagent12 




Table 3.4: Wittig reaction for the methylenation. 
 
Entry Reagents Conditions Remarks 
1 NaH (2.2 eq.), DMSO 75-80 oC (45 min), rt, 16 h S.M recovered 
2 LiHMDS (2.2 eq.), THF 0 oC- rt, 15 h S.M recovered 



















Table 3.5: PMP deprotection. 
 
 
Next, we just needed to deprotect the PMP group to produce the free amine. 
After trying several unsuccessful attempts (Table 3.5) we obtained the desired product 
by reverse addition i.e., 3-34 was added dropwise to a CAN solution. The free amine 
was protected with Boc to furnish 3-35. Compound 3-35 is important to us in two 
ways. It is a useful intermediate for the total synthesis of the target peptide and it can 
be used to prove our hypothesis of a cyclisation process during acidic hydrolysis of 
Entry Reagents Conditions Remarks 
1 
 
Iodosobenzene diacetate,13 MeOH 
 
 
rt, 1 h 
 
Mass found but 
complex NMR 
2 Trichloroisocyanuric acid,14 H2SO4  
 
rt, O/N  
 
Mass not found 
 
3 CAN, ACN/H2O15  
 








the natural peptide. The reaction conditions as applied for peptide degradation were 
thus performed on 3-35 and the cyclised product 3-36 was identified and isolated. 
Interestingly, it was found that the coupling constant between the α and β protons was 
12.0 Hz which supported our assumption that the relative stereochemistry was trans in 
the cyclic lactone 3-36. Next, Marfey’s reagent16 was used to couple with cyclic 
lactone 3-35 and the reaction mixture was injected to the LCMS and found it matched 


















































































































FDAA derivative of amino acid mixture 
















3.5      Conclusion 
In this chapter, we discussed the successful de novo asymmetric synthesis of a 
new non-proteinogenic amino acid (2-amino-3,4-dimethylpent-4-enoic acid). After 
attempting several strategies, 3-36 was successfully synthesised in five steps. This 
confirmed our hypothesis of a cyclisation process occuring under acidic condition. 
From the derivatisation technique using Marfey’s reagent, we established the absolute 
configuration of the 2-amino-3,4-dimethylpent-4-enoic acid fragment 2 of the natural 
product. So it was confirmed that the absolute configuration of 2-amino-3,4-
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Synthesis of 3-Amino-2-Hydroxy-2-Methylsuccinic Acid 
4.1 1st Generation synthesis from L-Tartaric acid 
After determining the absolute stereochemistry of the two amino acid 
fragments, we needed to synthesise the 3-amino-2-hydroxy-2-methylsuccinic acid. As 
we had no idea about the absolute stereochemistry of this fragment, our synthetic plan 
needed to be flexible to generate all four diastreomers possible for that fragment. L-
Tartaric acid 4-1 was treated with benzyl alcohol in the presence of TsOH to get the 
dibenzyl ester.1 The vicinal alcohol was converted to the cyclic sulfite 4-3 with 
SOCl2.2 To make a good electrophilic centre at the α-carbon, 4-3 was treated with an 
oxidant to afford the cyclic sulfate 4-4. The cyclic sulfate was opened up with sodium 
azide as the azide source to obtain the azido sulfate salt intermediate. Acidic 
hydrolysis of the salt generated azido-alcohol 4-5.3 Next, we needed to oxidise the 
secondary hydroxyl group to the ketone. Common oxidation methods failed most 
likely because the product keto-diester 4-6 was not stable. Being unsuccessful in 
oxidizing the azide intermediate, we thought to convert the azide to an amine under 
Staudinger reaction conditions4 and protect with Boc. Again, several oxidation 
conditions were attempted on 4-8 but none of them were successful. At this point, it 
was believed that the oxidised product might not be stable. So, we changed our 









Scheme 4.1: 1st Generation synthesis of β-disubstituted aspartic acid derivative. 
 
 
Table 4.1: Oxidation of azido-alcohol. 
 




OH 1. PPh3, H2OReflux, 6 h
2. (BOC)2O, Et3N
Dioxane /H2O
















Entry Reagents Conditions Remarks 
1 DMP, DCM rt, 16 h S.M 
2 Swern oxidation -78 oC, 4 h Unidentified product 





Table 4.2: Oxidation of Boc protected amino-alcohol (4-8). 
 
 
4.2 2nd Generation synthesis from hydroxyacetone 
In this protocol the primary alcohol group of hydroxyacetone was protected 
with TBS using standard reaction conditions. The HWE reaction was chosen to afford 
the olefin 4-12. Though we did not get good selectivity (E/Z=2.3/1), all four 
diastereomers of the diol 4-13 could be formed by just changing the geometry of the 
double bond and the AD-mix composition (α or β) in the Sharpless dihydroxylation 
reaction. To standardise the scheme, the pure E-isomer was carefully separated (Z- 
and E-isomers were confirmed by nOe studies and comparing with literature8 NMR) 
and treated with AD-mix β (Sharpless Asymmetric Dihydroxylation) to produce the 
diol 4-13. The cyclic sulfate 4-14 was obtained readily by following a similar reaction 
sequence as shown in Scheme 4.1. It was planned deliberately to synthesise 4-14 so 
that the cyclic sulfate can be opened with the azide regioselectively. Being α to the 
ester, electronically it is more eletrophilic than the β carbon (quaternary) centre of the 
cyclic sulfate. Steric effects also favour nucleophilic attack at the α-centre. With this 
Entry Reagents Conditions Remarks 
1 TEMPO, NaOCl NaBr, 
NaHCO3, EA/Toluene/Water5 
rt, 30 min. Complicated TLC 
2 RuCl3, mCPBA6  
 
rt, 2 h S.M 
3 DMP, DCM  
 
rt, 1.5 h Unidentified Polar spot 
isolated 
4 Trichloroisocyanuric acid, 
TEMPO7 
rt, 2 h Unidentified Polar spot 
isolated 
5 Swern oxidation -78 oC, 4 h S.M 





reasoning, 4-14 was treated with sodium azide in acetone/water at 50 oC for 7 h and 
consecutive biphasic (ether-water) acid hydrolysis yielded the azido alcohol 4-15 in 
70% yield. Gratifyingly, the expected regioselective product was obtained and 
confirmed by 13C-NMR and DEPT experiments. The azide was hydrogenated to 
amine, which was protected with CbzCl to afford 4-16. Standard reaction conditions 
(using TBAF in THF and HF in ACN) for cleaving the TBS group were employed but 













30% (Over two steps)
1. SOCl2, Et3N
DCM, 0 oC, 30 min.
2. RuCl3. XH2O, NaIO4
ACN/H2O (1:1.5)

















50 oC, 7 h
2. 20% H2SO4













1. Pd/C, H2,MeOH, O/N


























4.3 Sharpless Asymmetric Aminohydroxylation 
Following another strategy, the TBS protecting group of 4-12 (E/Z=2.3/1) was 
readily cleaved by standard reaction conditions to afford 4-19. Deprotection of TBS 
group afforded the readily separable E-isomer 4-19 because the resulting Z-isomer 
reacted with the ester intramolecularly to form a lactone. Jones oxidation of the free 
alcohol 4-19 produced the corresponding acid 4-20, which was converted to its benzyl 
ester by DCC coupling method. Sharpless asymmetric aminohydroxylation was tried 





Scheme 4.4: Sharpless asymmetric aminohydroxylation strategy. 
 
4.4 Sharpless Asymmetric Dihydroxylation 
We thus moved forward with the same Sharpless cyclic sulfate strategy to 
produce an azido alcohol. This time, however, the wrong regioisomer 4-26 was 


















AD-mix β, -1 oC
CH3SO2NH2, 48 h
83%















50 oC, 4 h
2. 20% H2SO4





Scheme 4.5: Sharpless asymmetric dihydroxylation strategy. 
 
  
4.5 Changing TBS group to benzyl group 
In an adoption of Scheme 4.3 the replacement of the TBS group of 4-12 with 
benzyl was planned such that a deprotection/reduction of the benzyl and azide groups 
could occur in a single step. Unfortunately, benzyl protection of the tri-substituted 
allylic alcohol was difficult. We tried this protection in basic medium with and 
without activator (TBAI) but reaction mixtures always produced complex mixture of 
compounds. Even neutral (Table 4.3, entry 3) reaction conditions were not successful. 
Eventually, freshly prepared benzyl 2,2,2-trichloroacetimidate (Bn-TCA) in the 
presence of TMS-triflate afforded the desired protected alcohol 4-27 in 50% yield. 
Next, following same reactions sequence as in Scheme 4.3, 4-28 was successfully 
prepared. As per our previous plan we attempted reduction of the azide and 
deprotection of the benzyl group in a single step by using Pd/C, H2 but the desired 
product 4-29 was not isolated. So it was planned to go for a stepwise reaction 
sequence because we suspected that even if we would get 4-29, it would be difficult to 















Scheme 4.6: Benzylation of tri-substituted allylic alcohol. 
 
 















Scheme 4.7: Debenzylation and azide reduction. 
   
 
Staudinger reaction11 was performed to reduce the amine which was protected 
with Fmoc to get 4-31 in 11% yield in two steps (Scheme 4.8). Later, it was found that 
in THF solvent the selective reduction of azide was obtained without cleaving the 
benzyl protecting group. Compound 4-31 was produced in 70% overall yield with this 
procedure. 
 
Entry Reagents Conditions Remarks 
1 NaH, BnBr, DMF 0  oC  to rt, 30 min. Complicated TLC 
2 NaH, BnBr, TBAI, THF9 40 oC, 12 h Polar  spot found 
3 Silver (I) Oxide, BnBr, DMF rt, 2 h No desired product 


















11% (over 2 Steps)4-28 4-30 4-31
20% w/w Pd-C, H2
THF, 4 h
70% (over 2 Steps)
 













Scheme 4.9: Debenzylation in presence of Fmoc group.  
         




It was again found difficult to deprotect the benzyl group of this substrate. In 
Lewis acid mediated (Table 4.4, entry 5) conditions, the resulting alcohol interestingly 
cyclised to produce a five membered lactone. To avoid the unwanted cyclisation, it 
was planned to synthesise the cyclic urethane, N,O-acetal,13 primary alcohol, acetal or 
ketal (4-34 to 4-37) and then deprotect the benzyl. Our first attempt to form the cyclic 
urethane 4-34 was unsuccessful. After various failures to construct the N,O-acetal 4-
Entry Reagents Conditions Remarks 
1 Pd/C, H2, MeOH rt, 12 h, 1 atm. S.M and trace amount of 
Fmoc cleaved product 
2 Pd/C, H2, MeOH rt, 5 h, 50 psi Complex TLC 
3 Pearlman’s catalyst, H2,  THF  rt, 2 h, 1 atm.  No desired product 
4 DDQ (10 eq.), DCM 40 oC, 72 h No desired product 







































Scheme 4.11: Attempt to form cyclic urethane. 
 
Here we thought Fmoc may create a steric problem due to its bulky size. So we 
planned to reduce the ester in presence of azide by LiBH4 and then form the acetal 
























Scheme 4.12: Reduction of ester and attempt to form ketal. 
 
The free hydroxyl group of 4-38 was then protected as TBDPS with TBDPSCl, 
imidazole and DMAP and then the benzyl group was attempted to be cleaved with 






















Scheme 4.13: TBDPS protection and debenzylation. 
 
  
4.6 Inserting p-Methoxybenzyl (PMB) group 
Adopting Scheme 4.3 we replaced the TBS group of 4-11 with PMB, so that 
the PMB group could help to improve high enantiomeric excess by the virtue of pi-pi 
interaction in the transition state15 of Sharpless asymmetric dihydroxylation reaction 
and also the cleavage of PMB would be relatively easy. In this new protocol (Scheme 
4.15) we faced the problem of preparing the PMB ether of hydroxyacetone. It was 
found that Dudley’s reagent produced the best results. After getting the PMB 
protected product, the azido-alcohol 4-46 was obtained following the same reactions 





asymmetric dihydroxylation was faster for the E-isomer 4-43 as compared to the Z-
isomer. The enantiomeric excess was also high for the E-isomer. The absolute 
stereochemistry was determined through functional group manipulation of 4-44 to the 
tetraol (Scheme 4.16) and compared with the optical rotation value found in the 
literature.16 Unfortunately, the PMB deprotection was not as easy as planned. Instead 
of getting the desired product, we got mainly the benzyl ester 4-53 when DDQ was 
used. As this benzylic oxidation was found when tertiary alcohol was not protected, 









Scheme 4.14: PMB protection of hydroxyacetone. 
 
 





Entry Reagents Conditions Remarks 
1 NaH, PMBBr, DMF 0  oC  to rt, 30 min. Complicated TLC 
2 NaH, PMBBr, TBAI, THF 40 oC, 12 h Polar  spot found 
3 PMB-TCA (Fresh), PPTS, 
DCM 
rt, 12 h 40% yield 
4 Dudley’s reagent,17 MgO, 
MeOTf, PhCF3 
 



























4-44 4-47 4-4887% Quantitative
0 oC, 1 h
10 % Pd-C





Scheme 4.16: Synthesis of tetraol for determining the absolute configuration. 
  
 
 Next, we thought to reduce the azide selectively to an amine and then to 
protect it with Cbz so that we would have more options to cleave the PMB ether. To 





depreotection. Compound 4-46 was reduced to the amine under hydrogenation 
conditions and protected with Cbz using standard reaction conditions to get 4-54. 
LiBH4 was used to produce the diol 4-55. CAN18 was applied to deprotect the PMB 
group which successfully afforded the triol 4-56. Our attempts (PDC in DMF and 





































































4-54 4-5576% (over two steps)
 
 





We were next interested to change the ethyl ester to benzyl ester to prevent 
lactone formation because the benzyl ester would be less reactive towards 
nucleophilic oxygen and it was thought that the benzyl ester and azide would be 
converted to acid and amine respectively in one step. The ethyl ester 4-46 was thus 
hydrolysed with LiOH in THF/H2O and then the carboxylate anion19 of 4-58 
(generated by Cs2CO3) was reacted with BnBr to obtain the benzyl ester 4-59. As it 
was known from the previous experience that the tertiary alcohol must be protected to 
stop formation of the side product, the TBS group was chosen for protection. 
Unfortunately the TBS protection did not work because of steric effects of the 




Scheme 4.19: Functional group manipulation. 
 
 
After failure to protect the tertiary hydroxyl group, PMB deprotection was 
successfully performed with CAN, but again attempted oxidation methods (Swern,20 





























Scheme 4.20: Oxidation of primary alcohol. 
 
 
At this point, we believed that the tertiary alcohol must be protected before 
oxidation of the adjacent primary alcohol. The reaction sequence was changed for this 
purpose. First, the TBS group was attached in 4-46 and then hydrolysis of the ethyl 
ester 4-63 was attempted to generate the free acid 4-64 which was planned to be 
converted to its benzyl ester for the above mentioned reasons. Here again, the desired 
compound was not generated, but instead migration of the TBS group took place 






































Figure 4.2: TBS migration due to high functional density in the small molecule. 
  
 
At this juncture, two things seemed crucial: i) protect the tertiary alcohol 
before oxidation and ii) change the ethyl ester into another functional group to avoid 





reduce cost and time (Scheme 4.22). For protection of tertiary alcohol 4-46R, TES 

















































Scheme 4.22: Functional group manipulation. 
 
 
Table 4.6: Oxidation studies of 4-68R. 
 
 
The TES group was put on the tertiary alcohol 4-46R by using TESOTf 
(TESCl did not work because of its reduced reactivity and steric repulsion) and 
triethylamine (Et3N). Under optimised conditions, it was found that the reduction of 
the ester 4-65R by LiBH4 in diethylether (Et2O) produced alcohol 4-66R in 80% 
isolated yield. The free alcohol 4-66R was protected as its acetate 4-67R and then the 
Entry Reagents Conditions Remarks 
1 PCC, DCM rt, 14 h Trace amount of product 
2 Swern -78 oC S.M recovered 
3 Parikh-Doering rt, 14 h S.M recovered 
4 TPAP, NMO, DCM22 rt, 14 h 50% yield but not reproducible 





PMB group was deprotected successfully to 4-68R using DDQ.24 Various oxidation 
methods were tried and finally the aldehyde 4-69R was successfully generated under 
TEMPO conditions (Table 4.6, entry 5) which was immediately converted to the 
carboxylic acid 4-70R under mild Pinnick oxidation25 conditions. Interestingly the 
TES group hydrolysed off during the Pinnick oxidation step. From previous 
experience to allow easy handling of intermediates, it was planned to protect both the 
carboxylic acid and the tertiary alcohol of 4-70R. Our attempt to protect the 
carboxylic acid 4-70R as tert-butyl ester using standard conditions was unsuccessful. 
A relatively more efficient method26 with (Boc)2O and DMAP was thus employed to 
prepare the corresponding ester. Interestingly, this reactive reagent combination not 
only generated the tert-butyl ester, but it also protected the tertiary alcohol as its tert-
butyl carbonate 4-71R. Surprisingly, acetate deprotection failed under K2CO3 in 
MeOH. Interestingly, the Boc group migrated to the primary alcohol very quickly 














Figure 4.3: Boc migration in strong basic medium. 
  
We next changed the ethyl ester group of 4-46R to an amide (Scheme 4.24) to 
inhibit lactone formation during PMB deprotection. For this, 4-46R was hydrolysed to 
its acid 4-76R and then converted to its ethyl amide 4-77R. The tertiary alcohol was 
first TES protected before PMB deprotection by DDQ. In this case, we were happy to 
get the free alcohol 4-79R. Unfortunately, various oxidation attempts were not 










Table 4.7: Oxidation studies of 4-79R. 
 
 
After several sets of failures in functional group manipulation to get the 
desired amino acid, it was necessary to search for an alternative plan to prepare the 
amino acid 4-18R. In this study, we found that Schöllkopf’s auxiliary27 may be best 
suited for that purpose, although there are limited examples to explore the generation 

























The ideas behind choosing this auxiliary were as follows: 
1) Potentially it is possible to generate all four isomers. 
2) In a single reaction, it is possible to get two diastereomers because the newly 
formed chiral centre should be controlled by the chiral centre already present 
in the auxiliary.  
Entry Reagents Conditions Remarks 
1 PCC, DCM rt, 14 h Trace amount of product 
2 DMP, DCM 0 oC to rt, 14 h Complex TLC 
3 Parikh-Doering 0 oC to rt, 14 h TES group migration 
4 TPAP, NMO, DCM rt, 14 h TES group migration 
















































In our plan, we converted pyruvic acid to its benzyl ester and that was used as 
the electrophile with the Schöllkopf’s auxiliary 4-81 in the presence of BuLi (Scheme 
4.25). The desired coupling product was obtained but four diastereomers were found 
instead of two. After careful column chromatography, we obtained the major isomers 
4-82 and 4-83 but one of them was contaminated with another isomer (Figure 4.4). 
The absolute stereochemistry of the products was assumed from theory but we did not 
know which one was which stereoisomer. In the next step, the most pure fraction was 
subjected with 0.25M HCl to cleave the auxiliary. The resulting amine 4-85 was 
converted to its Boc protected form 4-86. The yield of the reaction was poor (20%) 
but still we proceeded further by cleaving the benzyl ester and hydrolysing the methyl 


































100 oC, 16 h
4-84 4-85
4-86 4-87 4-88




Scheme 4.26: Cleaving of auxiliary. 
 
 
Poor stereoselectivity made Schöllkopf’s protocol difficult to use for 
determining the absolute stereochemistry of the amino acid present in the natural 
peptide. Returning to a previous scheme, it was thought that deprotection of the PMB 
of 4-65R in buffered condition (towards neutral pH) may produce the desired free 
alcohol (because lactone formation was facilitated in acidic or basic medium). It was 
first tried using DDQ in pH 7.5 (Phosphate buffer)28 and despite previous failures the 
primary alcohol 4-89R was obtained in excellent yield. Next, BAIB and TEMPO were 
found to be the best combination (developed by Margarita)23 for the problematic 
oxidation step to produce the aldehyde from 4-89R. The resulting aldehyde was 
oxidised to acid by mild Pinnick oxidation to generate 4-90R in moderate yield. In the 
Pinnick oxidation, the quaternary TES group deprotected reasonably via migration to 
form a silylester and hydrolysis during acidic workup. The azide reduction and ester 
hydrolysis were performed next to prepare the desired amino acid 4-18R in racemic 
form. With the amino acid in hand, it was coupled with Marfey’s reagent29 and 









Scheme 4.27: PMB deprotection under buffered pH 7.5. 
 
 
As 4-18R was racemic, this would clarify two aspects: if one isomer matched 
then we needed to synthesise one of the two anti-isomers but if none matched, then we 
should concentrate synthetic effort on its syn-isomers. Since none matched (Figure 
4.5), we concluded that one of the syn isomers would be present in the natural peptide. 
To synthesise the syn-amino acid, we needed to use the Z-isomer 4-92 (Scheme 4.28). 
First, we chose to use AD-mix α because we knew that it gave 80% ee of diol 4-93, so 
10% of the other enantiomer would be present for comparison purposes after Marfey’s 
derivatisation during LCMS. Thus, following the established synthetic strategy 
(Scheme 4.28) we made the (2S, 3S) isomer of the desired amino acid 4-99 in 80% ee 
and found that the major enantiomer exactly matched with the amino acid present in 

























































Figure 4.5: LCMS of mixture of two diastereomers.  
  
In the conclusion, the absolute stereochemistry of the amino acid present in the 





















Two diastereomers (anti, OH-NH2) because racemic
















1. SOCl2, Et3N, DCM






-1 oC, 96 h
85%


















1. TESOTf , Et3N, DCM

























































































Figure 4.6: LCMS chromatogram for comparison. 
 
After knowing the fact that we needed more of the Z-olefin 4-92 to prepare the 
specific amino acid enantiomer 4-99, we need to improve the Z selectivity (Scheme 
4.29). Thus the Still-Gennari modification30 of the HWE reaction was tried and gave 
moderately better selectivity, however, separation of the two isomers was still tedious 






















1. NaH, THF, rt, 20 h E/Z= 1:1 (50%)
2. KHMDS, 18-crown-6 E/Z= 1.6:1 (22%)
 
 
Scheme 4.29: Still-Gennari HWE modification. 
 
It was thus decided to perform the conjugate addition of a Gilman reagent to 
an alkyne ester to generate the tri-substituted Z-olefin (Scheme 4.30). We started with 
the protection of propargyl alcohol 4-100 with PMB-Cl and then the terminal alkyne 
4-101 was coupled with ethyl chloroformate to prepare 4-102 in 96% yield.31 
Me2CuLi was prepared freshly and then used for Michael addition to alkyne 4-102 at 
the β-carbon to get the Z-isomer exclusively.32 Scaling up of this reaction was found 
problematic in order to maintain exclusive Z-selectivity. This was solved by extensive 
standardisation of the workup procedure, whereby double-bond isomerisation was 








-78 oC, 1 h
Me2CuLi, THF



















Having a good method to generate the Z-isomer of the ethyl ester, we next 
planned to synthesise the all methyl ester of the whole natural and synthetic peptide 
for a direct comparison without resorting to an ester hydrolysis step. We reasoned that 
this strategy would save one step and facilitate our aim without purification and 
isolation problems on small scales (the final peptide would also be highly polar and 
may be to some extent water soluble, so there would be a possibility to lose some 











Finally, we reformed our whole synthetic scheme for the methyl ester version 
as depicted in Scheme 4.31. In our previous Scheme 4.28, we obtained the ethyl ester 
4-97 in 1.7% overall yield in 9 steps. Here, the methyl ester 4-109 was prepared in 
16% overall yield in 9 steps with better enantiomeric purity (82% ee) in the SAD 
reaction of methyl ester 4-104. 
4.7 Conclusion 
In this chapter we described our synthetic studies to prepare all the isomers of 
the desired amino acid 3 and determined the absolute stereochemistry of the amino 
acid present in the natural peptide N1708. The desired amino acid precursor 4-109 
was obtained in 16% overall yield in 9 steps. The absolute configuration of the amino 
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Synthesis of 5-Methyl-3,4 Decanoic Acid 
5.1 Asymmetric methylation using Evan’s chiral auxiliary 
The fatty acid moiety 4 was the last fragment to be synthesised before we 
engaged in the total synthesis.  As we did not isolate this part from natural product 
hydrolysis, it was required to be synthesised in both enantiomeric forms to finish the 
full molecule. HPLC and NMR comparison between the two diastereomers of the 
whole synthetic peptide and the isolated peptide would then confirm the absolute 
configuration of the fatty acid in the lipopeptide. For asymmetric methylation, one of 
the best and easy choices is to use Evan’s auxiliary. Normally, Evan’s auxiliary is 
coupled to the carboxylic acid using BuLi but this was found inefficient with 
heptanoic acid in our hands. We thus used a modified method to attach the auxiliary to 
the heptanoic acid using a mixed anhydride strategy in the presence of LiCl.1 
The methylation2 step was attempted using different strong bases (Table 5.1) 
and LDA was found to be the best. The auxiliary was cleaved by reduction3 of 5-4 to 
afford alcohol 5-5. LiBH4 in Et2O produced better results than those reported. 
Oxidation of the primary alcohol was performed carefully with relatively mild 
methods in order to reduce the chance of a potential racemisation at the α-centre of the 
resultant aldehyde. Unfortunately, the isolated yield of the oxidation step was not 









Scheme 5.1: 1st Generation synthetic plan of fatty acid portion. 
 




















Figure 5.1: LCMS data for asymmetric methylation. 
Entry Reagents Conditions Remarks 
1 NaHMDS, THF -78 oC to rt, 16 h 48% 
2 KHMDS, THF -78 oC to rt, 16 h 53% 









































Scheme 5.2: Model study for sulfone formation and olefination reaction. 
 
5.2 Model studies of Julia-Kocienski olefination 
We targeted a fatty aldehyde unit 5-6 because it would be one of our substrates 
for the Kocienski modified Julia olefination reaction. The thioether 5-9 was thus 
synthesised by combining tert-butyl-3-bromopropanoate and tetrazol 5-8 in basic 
conditions.4 Thioether 5-9 was converted to sulfone 5-10 by oxidation with 
hexaammonium heptamolybdate. In our model study for olefination, we first used 
pentanal in the presence of LiHMDS at low temperature to produce the olefin in 16% 
yield. We also tried with heptanal using the same reacting conditions but did not 
obtain the desired product at all. From the literature, NaHMDS normally produces 
better yields. We thus used NaHMDS and achieved a 34% yield of 5-13. Next, we 
wanted to use the same reaction conditions on our targeted fatty aldehyde 5-6. This 
generated trace amounts of the desired olefin product. As the yield of 5-6 was too low 
and the olefination reaction was not efficient, we reversed the sulfone and aldehyde 
counterparts. The idea behind this change was to gain ready access to the two 








































































Figure 5.2: Mechanism of Julia-Kocienski olefination. 
 
5.3 2nd Generation synthetic plan 
In this new strategy, alcohol 5-5 was converted to the thioether 5-14 by 
Mitsunobu reaction (Scheme 5.4). Following the same oxidation method (Scheme 5.2), 
sulfone 5-15 was prepared. Using the reported method, TBDPS protected 3-carbon 
aldehyde 5-17 was obtained readily. We succeeded to produce reasonable amounts of 
the two counterparts for the olefination reaction, hopefully sufficient material to 
prepare enough fatty acid. Kocienski’s modified5 olefination procedures using two 
different bases showed that the best selectivity (E/Z=92:8) as measured by GCMS, 
was obtained using KHMDS. With 5-18 in hand, the TBDPS group was deprotected 





circumvent potential double bond migration to produce a more stable α, β-unsaturated 
aldehyde, the desired carboxylic acid was obtained directly using Jones oxidation, 
albeit in poor yield. While Jones reagent was added to the alcohol, considerable 
amount of the ester was formed; however, the reverse addition technique reduced 










































H2O2, EtOH, 8 h
26-42%
55%
(E/Z=78:22 By GC, M=Na)








































































                 
 
 
















Scheme 5.5: Oxidation studies. 
 




5.4 Synthesis of other enantiomer of the fatty acid 
We prepared the R-isomer of the alcohol unit 5-5׳ with the help of the other 
enantiomer of the Evan’s auxiliary by following the same procedure as established 
(Scheme 5.1). Mitsunobu reaction conditions produced 5-14׳ in 76% yield. The 
sulfone 5-15׳ was obtained by oxidation with hexaammonium heptamolybdate. Next, 
Kocienski’s modified procedure was applied to produce 5-18׳. Standard TBAF 
mediated conditions produced free alcohol 5-19׳ followed by Jones oxidation afforded 
desired fatty acid 5-20׳ with (R) configuration (Scheme 5.6). 
 
 
Entry Reagents Conditions Remarks 
1 TEMPO, BAIB, ACN/H2O6  0 oC to rt, 16h 15% 
2 TPAP, NMO, Acetone7 0 oC to rt, 16h No reaction 










In this chapter, we successfully synthesised two enantiomers of the desired 
fatty acid (5-20 and 5-20׳) for preparing the whole peptide. In this strategy, we used 
Evan’s auxiliary-directed asymmetric methylation and Kocienski-modified Julia 
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Coupling of Fragments & Full Structural Assignment  
6.1 Peptide coupling 
 
Having all fragments in hand, we needed to synthesise the whole peptide. As 
we were unsuccessful in isolating the fatty acid residue of the natural lipopeptide, we 
had to prepare two possible diastereomers to compare with the isolated natural product. 
To save materials, it was planned to prepare the whole peptide as its trimethyl ester. 
The advantages are: i) the trimethyl ester could be directly compared with the isolated 
natural peptide (as it is easy to convert the tricarboxylic acid to its trimethyl ester) 
avoiding a peptide hydrolysis step; ii) isolation and purification of the resulting triacid 
from the hydrolysis of the synthetic peptide might be difficult on a small scale due to 
its polarity at the late stage; and iii) we would obtain more characteristic proton signal 









It was reasoned that the sequential linear coupling of the amino acid fragments 
and then the fatty acid would be more a logical choice over a convergent coupling 
sequence because we needed to attach two enantiomers of the fatty acid portion to the 
common tripeptide unit to obtain the two possible structures of the final peptide. L-
aspartic acid was thus converted to the dimethyl ester hydrochloride salt 6-2 using 
SOCl2 in MeOH.1 Compound 3-35 was hydrolysed to its free carboxylic acid to 
couple with 6-2 to prepare 6-3 in good yield. Deprotection of the Boc group was 
performed by TFA to yield the TFA salt 6-4 quantitatively, which was ready for the 
synthesis of the tripeptide (Scheme 6.2). 
 Next, we wanted to reduce the azide of 4-109 and protect the free amine before 
coupling to the dipeptide. Initially we chose Fmoc because its UV activity would help 
to purify the tripeptide by prep HPLC on small scale. Catalytic hydrogenation 
followed by standard Fmoc protection2 was performed to obtain 6-6 which was then 
coupled to 6-4 to generate the tripeptide 6-7. It was found that the latter coupling 
reaction was inefficient and the isolated yield was about 10%. We pushed forward to 
get the free amine, which proceeded in a messy fashion and only trace amounts of the 

























Scheme 6.3: Boc protection. 
 
 
These practical limitations forced us to switch the protecting group to Boc. We 
used biphasic conditions as well as base free conditions (Scheme 6.3), but none of 
them turned out to be clean; only 10-15% isolated yields were obtained. At this point 
we changed the sequence of reactions. We used Staudinger reaction to reduce the 
azide in the presence of PMB group to generate the free amine 6-11 and then 
protected with Boc, which was then subjected to hydrogenation conditions to cleave 
the PMB group and prepare the free alcohol 6-13. This functional group manipulation 










Scheme 6.4: Functional group manipulation. 
 
 
As the above scheme was inefficient, we tried to improve reaction yields using 
other methods. We made an effort to synthesise 6-13 in one step from 6-10 using 
hydrogenation conditions in the presence of (Boc)2O (Scheme 6.5).3 Interestingly, it 
was noticed (by TLC monitoring) that in addition to the desired product 6-13, 
considerable amounts of 6-12 and TES group migrated 6-14 were also present in the 



























This observation indicated that azide reduction and Boc protection were faster 
than the PMB deprotection. In our next plan for the preparation of 6-13 the oxidative 
cleavage of the PMB group was attempted on 6-12 under buffered conditions4 but 























Scheme 6.6: Oxidative cleavage of PMB. 
 
 
To circumvent these inefficiencies, we thought to couple the azido acid 4-109 
directly with the dipeptide 6-4 to generate tripeptide 6-15 with an azide functionality 
and then generate the free amine by Staudinger reaction. We accomplished 6-15 in 
50% isolated yield by using standardised coupling reaction conditions. As our azide 
was situated near to the quaternary centre, the bulky common reagent Ph3P was 
reasoned to be a bad choice for the reduction of the azide present in the tripeptide. It is 
also known that Ph3P(O) (side product when Ph3P is used for Staudinger reaction) 
could create an issue during purification. For these two reasons, we used the more 
reactive Bu3P for the azide reduction, but unfortunately the azido-reduction did not 
occur. Eventually we used Me3P that has been reported by the Nicolaou group for 


































































Staudinger reaction using the reactive and small phosphine Me3P was 
performed on 6-15 under slightly modified reaction conditions gave 6-8 in 70% yield. 
This free amine was then coupled with the two enantiomers of the fatty acid to 
generate two diastereomers. After obtaining the trimethyl ester of the natural 
lipopeptide, we wanted to convert our isolated natural product to its trimethyl ester 
derivative for comparison purpose. In this case, we used the less toxic TMSCHN2 in 









































For the convenience of NMR analysis, we named the different trimethyl esters 
according to the chiral centre present in the fatty acid portion (N represents the 




Figure 6.1: Alphabetic representation of the full peptide structure.  
 
We next recorded the 1H-NMR (500 MHz) and 13C-NMR (125 MHz) of the 
three compounds in CD3OD and CDCl3. In methanol, no significant difference was 
observed in their chemical shift values but in chloroform significant differences in 













13C NMR in CDCl3 in 125 MHz : 
 
 (S)  (N)  (R) 





























































































































































Table 6.1: Chemical shift values (δppm). 
 
We first plotted the differences between the two diastereomers R and S and 
found significant difference at C-9 and C-10 (all the carbons were assigned according 





carbons are part of the fatty acid portion and are near to the chiral center of interest 




Figure 6.2: Differences of chemical shift of corresponding carbon between S and R.  
 
 
Next, we plotted the differences of the corresponding carbon between N to S 
(in blue) and N to R (in maroon) in a single plot for easy visualisation and found the 
C-9 and C-10 of S being much closer in value to N as compared to R (the blue colour 
for C-10 is absent which means equal in value to N and the blue colour is very short 





Figure 6.3: Comparison of differences in 13C NMR (in CDCl3) among N, S and R 
forms of lipopeptide N1708. 
 
 





The LCMS (10% to 100% ACN/H2O) for all three components were found to 
display similar retention times (∆RT for S was 0.01 min. whereas ∆RT for R was 0.05 
min.). The colour code representation and LCMS data gave us confidence to conclude 
primarily that the S diastereomer is closer to the natural form N.   
 














Figure 6.4: LCMS Chromatogram of S. 












Figure 6.5: LCMS Chromatogram of N. 














Figure 6.6: LCMS Chromatogram of R.  
 
 
We measured the optical rotations {[α]25D = +31.6 (c = 0.18) for N, [α]25D = 
+18.8 (c = 0.25) for S and [α]25D = -23.1 (c = 0.22) for R} which confirmed the (S) 
∆RT = 0.01 





configuration of the fatty acid. Finally, we tried to hydrolyse 6-16 with Bu3SnOH at 
80 oC for 48 h; however ESI mass indicated the diacid as the major product. We 
believed that the poor solubility in DCE might be the factor for not getting the fully 
hydrolysed triacid. With this assumption, the crude diacid was dissolved in 
THF/H2O/MeOH and treated with LiOH at 0 oC and allowed to stir for 12 h and 6-18 
was obtained. The NMR data and optical rotation value of 6-18 ([α]25D = -20.0 (c = 0.1) 
for 6-18 and [α]25D = -23.7 (c = 0.3) for isolated natural lipopeptide N1708) were in 
accordance with the isolated natural product N1708. 
 
 





















Figure 6.7: 1H-NMR (500 MHz) comparison in CD3OD. 
 
 










In summary, we established the absolute stereochemistry of each amino acid 
fragment of the lipopeptide N1708 individually and then through total synthesis of 
two possible diastereomers confirmed the absolute stereochemistry of the fatty acid 
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Unless stated otherwise, all non-aqueous reactions were performed in flame-dried 
round bottom flasks under an inert argon atmosphere with freshly distilled dry solvents 
under anhydrous conditions. Tetrahydrofuran (THF) was distilled over 
sodium/benzophenone. Dichloromethane (CH2Cl2) was distilled over CaH2. 
Commercial reagents were purchased from Sigma Aldrich, Fluka, Merck, Alfa Aesar 
or Strem Chemicals, and used as received without further purification. 4Å molecular 
sieves were activated by heating in a furnace at 300 °C for 20 h before storing in a dry 
dessicator, which would be heated at 200 ºC under high vacuum for 15-20 min 
immediately prior to use. Yields refer to chromatographically and spectroscopically 
homogeneous materials, unless otherwise stated. Reaction progress was monitored by 
analytical thin layer chromatography (TLC) with 0.25 mm E. Merck pre-coated silica 
gel plates (60F-254) using UV light (254 nm) as visualising agent, and ceric 
ammonium molybdate, KMnO4 or ninhydrin as developing stains. Flash 
chromatography was performed on silica gel 60 (0.040 – 0.063 mm) purchased from 
SiliCycle or ACME Research Support. 1H NMR and 13C NMR spectra were recorded 
on a Bruker AMX500 (500 MHz) and Bruker ACF300 (300 MHz) NMR spectrometer 
at ambient atmosphere. 2D NMR was performed on a Bruker AMX500 (500 MHz) 
NMR spectrometer. The deuterated solvents used were CDCl3 and CD3OD. Chemical 
shifts are reported in parts per million (ppm), and residual undeuterated solvent peaks 
were used as internal reference: proton (δ 7.26), carbon (δ 77.0) for CDCl3 and proton 
(δ 3.31), carbon (δ 49.0) for CD3OD. 1H NMR coupling constants (J) are reported in 
Hertz (Hz), and multiplicities are presented as follows: s (singlet), d (doublet), t 





resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI 
mode. High resolution ESI mass spectra were obtained on a Bruker micrOTOF-Q II. 
Shimadzu LCMS-IT-TOF spectrometer was used for comparing retention time. Mass 
samples were dissolved in CH3OH (HPLC Grade), unless otherwise stated. Samples 
for infra-red measurements were prepared as thin films neat or in CH2Cl2 solution 
spread on NaCl cells, and spectra were recorded on a IRPrestige-21 Shimadzu FTIR 
spectrometer. Optical rotations were recorded on a Jasco DIP-1000 polarimeter with a 
sodium lamp of wavelength 589 nm. Enantiomeric excess was determined by chiral-




  General procedure for the preparation of Marfey’s derivative: To a 
solution of the amino acid (1.5 mg) in H2O (500 µL) were added FDAA (50 µL, 1 
mg/100 µL acetone) and NaHCO3 (50 µL, 1M solution) at rt. The reaction mixture was 
heated at 40 oC for 1 h and quenched with 2M HCl at rt. The solvent was evaporated 
under reduced pressure to obtain a residue which was dissolved in MeOH/H2O (1:1) 
before LCMS analysis.     
 
Chapter 3:  
 
 
Preparation of compound 3-2: To a solution of dry HCl (2.2 g, 60.1 mmol) in 
dry MeOH (40 mL) was added compound 3-1 (5.0 g, 37.56 mmol) slowly at 0 oC and 
the reaction mixture was stirred at that temperature. After 30 minute, Et2O was added 
slowly until slight white precipitate appeared and the reaction mixture was kept in the 





after one hour and then filtered off. The residue was recrystallised from EtOH/ Et2O to 
obtain pure mono ester 3-2 (5.7 g, 83%) as a white crystalline solid. 
1H NMR (DMSO, 300 MHz): δ 8.62 (3H, br), 4.16 (1H, t, J = 5.8 Hz), 3.64 (3H, s), 
2.99-2.97 (2H, dd, J = 6.0, 1.7 Hz). 
 
 
Preparation of compound 3-3: To a solution of 3-2 (4.6 g, 25.1 mmol) in 
dioxane/water (75 mL, 2:1) was added Na2CO3 (5.3 g, 50.2 mmol) slowly at 0 oC and 
the reaction mixture was stirred for 10 minute. (Boc)2O (6.34 mL, 27.6 mmol) was 
added to the reaction mixture at 0 oC and stirred for 10 h at rt. After completion of the 
reaction, it was acidified with a saturated NaHSO4 solution to pH 2.5 and extracted 
with Et2O. The organic layer was washed with brine and dried over Na2SO4. Removal 
of the solvent under reduced pressure afforded pure 3-3 (4.4 g, 71%) as a viscous 
material. 
Rf = 0.25 (TLC, 10% MeOH/CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 5.57 (1H, d, J = 
8.2 Hz), 4.63-4.60 (1H, m), 3.70 (3H, s), 3.01-3.00 (1H, dd, J = 6.2, 1.8 Hz), 2.88-2.82 
(1H, dd, J = 6.2, 1.8 Hz), 1.44 (9H, s). 
 
 
Preparation of compound 3-4: To a solution of 3-3 (1.0 g, 4.04 mmol) in 
CH2Cl2 (10 mL) were added DCC (1.0 g, 4.84 mmol), tBuOH (0.4 mL, 4.44 mmol) 
and DMAP (40 mg, 0.32 mmol) at 0 oC and the reaction mixture was stirred for 11 h at 





was washed with brine and then dried over Na2SO4. The solvent was removed under 
reduced pressure to get the crude material which was purified by column 
chromatography over silica gel (7.0% EtOAc/hexane) to obtain pure 3-4 (800 mg, 
66%) as a colourless oil. 
Rf = 0.4 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 5.42 (1H, br), 
4.45-4.42 (1H, m), 3.68 (3H, s), 2.97-2.90 (1H, dd, J = 11.5, 5.1 Hz), 2.79-2.72 (1H, 
dd, J = 11.5, 5.1 Hz), 1.45-1.43 (18H, s). 
 
 
Preparation of compound 3-5: To a solution of 3-4 (100 mg, 0.33 mmol) in 
freshly dried THF (1.0 mL) were added LiHMDS (0.37 mL, 1.0 M soln. in THF, 0.37 
mmol) and BuLi (0.25 mL, 1.6 M soln. in THF, 0.40 mmol) at -78 oC and the reaction 
mixture was allowed to warm to rt slowly over the period of 30 minute. The reaction 
mixture was again cooled back to -78 oC and MeI (83 µL, 1.32 mmol) was added 
dropwise. The reaction mixture was stirred for 16 h before quenching with dropwise 
addition of a saturated NH4Cl solution at -78 oC. It was then extracted with Et2O and 
the organic layer was washed with brine and dried over Na2SO4. The solvent was 
removed in vacuo to get the crude material which was carefully purified by column 
chromatography over silica gel (3% EtOAc/hexane) to obtain 3-5a (16 mg, 15%) and 
3-5b (7 mg, 7%) as colourless oil. 
Rf = 0.4 (TLC, 15% EtOAc/hexane) for 3-5a; 1H NMR (CDCl3, 300 MHz): δ 5.35 (1H, 
d, J = 8.7 Hz), 4.50-4.46 (1H, m), 3.68 (3H, s), 3.16-3.12 (1H, m), 1.46 (9H, s), 1.45 





Rf = 0.35 (TLC, 15% EtOAc/hexane) for 3-5b; 1H NMR (CDCl3, 300 MHz): δ 5.22 
(1H, d, J = 7.6 Hz), 4.51 (1H, m), 3.70 (4H, s), 3.13-2.92 (1H, m), 1.46 (9H, s), 1.44 
(9H, s), 1.19 (3H, d, J = 7.2 Hz). 
 
 
Preparation of compound 3-8: To a solution of 3-3 (0.5 g, 2.02 mmol) in dry 
DMF (6 mL) were added Cs2CO3 (1.32 g, 4.04 mmol) and BnBr (0.73 mL, 6.06 mmol) 
at 0 oC and the reaction mixture was stirred for 14 h at rt. After completion of the 
reaction, it was extracted with Et2O and the organic layer was washed with brine and 
dried over Na2SO4. The solvent was removed under reduced pressure to get the crude 
material which was purified by column chromatography over silica gel (10% 
EtOAc/hexane) to obtain pure 3-8 (550 mg, 80%) as a colourless oil. 
Rf = 0.4 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.34 (5H, s), 5.51 
(1H, d, J = 8.2 Hz), 5.21 (1H, d, J = 12.3 Hz), 5.15 (1H, d, J = 12.3 Hz), 4.63-4.60 
(1H, m), 3.62 (3H, s), 3.06-2.98 (1H, dd, J = 17.3, 4.8 Hz), 2.86-2.78 (1H, dd, J = 
17.3, 4.8 Hz), 1.43 (9H, s). 
 
Preparation of compound 3-10: To a solution of 3-2 (1.0 g, 5.45 mmol) in 
Et2O/water (24 mL, 1:3) were added K2CO3 (1.05 g, 7.63 mmol) and benzyl 
chloroformate (1.08 mL, 7.63 mmol) at 0 oC and the reaction mixture was stirred for 4 
h at rt. After completion of the reaction, it was acidified with 1M HCl and then 
extracted with EtOAc. The organic layer was washed with brine and dried over 





free acid which was converted to 3-10 (780 mg, 42% over two steps) as a colourless 
oil by following the same procedure described above for 3-4. 
Rf = 0.35 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.36-7.32 (5H, 
m), 5.71 (1H, d, J = 7.9 Hz), 5.11 (2H, s), 4.54-4.48 (1H, m), 3.67 (3H, s), 3.01-2.94 
(1H, dd, J = 16.8, 4.4 Hz), 2.84-2.77 (1H, dd, J = 16.8, 4.4 Hz), 1.44 (9H, s); 13C NMR 
(CDCl3, 75 MHz): δ 171.11, 169.49, 155.89, 136.22, 128.47, 128.11, 128.04, 82.55, 
66.95, 51.82, 50.93, 36.78, 27.80. 
 
 
Preparation of compound 3-12: To a solution of 3-4 (0.66 g, 2.18 mmol) in 
acetone/water (30 mL, 4:1) was added NaOH (130 mg, 3.26 mmol) slowly at 0 oC and 
the reaction mixture was stirred for 1 h. After completion of the reaction, it was 
acidified with 5% aq. NaHSO4 solution up to pH 3.0. The reaction mixture was 
extracted with EtOAc and the organic layer was washed with brine and dried over 
Na2SO4. Removal of the solvent under reduced pressure afforded pure 3-12 (440 mg, 
70%) as a viscous material. 
Rf = 0.25 (TLC, 10% MeOH/CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 5.47 (1H, d, J = 











Preparation of compound 3-13: To a solution of 3-12 (0.50 g, 1.73 mmol) in 





CSA (80 mg, 0.35 mmol) and then the reaction mixture was heated at 90 oC for 3 h. As 
the reaction completed, it was extracted with EtOAc and the organic layer was washed 
with sat. NaHCO3 solution and brine. The collected organic layer was dried over 
Na2SO4. The solvent was removed under reduced pressure to get the crude material 
which was purified by column chromatography over silica gel (10% EtOAc/hexane) to 
obtain pure 3-13 (230 mg, 44%) as a white solid. 
Rf = 0.45 (TLC, 20 % EtOAc/hexane); IR (KBr): vmax =2983, 2932, 1748, 1717, 1480, 
1409, 1245, 1156, 1005 cm-1; 1H NMR (CDCl3, 300 MHz): δ 5.87-5.72 (1H, m), 5.19 
(1H, d, J = 8.7 Hz), 4.59-4.43 (1H, m), 3.0 (1H, m), 2.82-2.73 (1H, dd, J= 10.8, 16.0 
Hz), 1.45 (18H, s); 13C NMR (CDCl3, 75 MHz): δ 169.18, 152.34, 82.71, 72.50, 52.63, 
32.06, 27.95, 27.76; (ESI-MS): m/z  [M+Na]+ 324.0. 
 
 
Preparation of compound 3-14: To a solution of 3-13 (0.40 g, 1.33 mmol) in 
dry DME (12 mL) was added tert-butoxybis(dimethylamino) methane (Bredereck’s 
reagent) (0.8 mL, 3.98 mmol). A solution was heated to reflux for 15 h and the solvent 
was removed in vacuo. The residue was purified by column chromatography over 
silica gel (40 % EtOAc/hexane) to obtain 3-14 (360 mg, 76%) as a yellow viscous 
material. 
Rf = 0.30 (TLC, 50% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.68 (1H, s), 
5.72 (1H, s), 5.48 (1H, d, J = 9.6 Hz ), 5.26 (1H, d, J = 9.6 Hz), 3.16 (6H, s), 1.48 (9H, 
s), 1.45 (9H, s); 13C NMR (CDCl3, 75 MHz): δ 169.77, 152.10, 86.01, 82.29, 72.29, 






Preparation of compound 3-15a and 3-15b: To a solution of 3-14 (0.35 g, 
0.98 mmol) in EtOAc (15 mL) was added 10% palladium on carbon (175 mg, 50% 
w/w). The reaction was stirred under hydrogen atmosphere (1 atm) for 3 days at rt and 
filtered through Celite. The solvent was removed in vacuo and the residue was purified 
by column chromatography over silica gel (10% to 15% EtOAc/hexane) to obtain 3-
15a (130 mg, 42%, crystallized from Et2O/Hexane, mp 80 oC) and 3-15b (100 mg, 
33%, mp 90 oC) as white solids. 
Rf = 0.50 (TLC, 20% EtOAc/hexane) for 3-15a; 1H NMR (CDCl3, 300 MHz): δ 5.94-
5.75 (1H, m), 5.17-5.14 (1H, m), 4.05-3.90 (1H, m), 2.95-2.85 (1H, m), 1.50 (9H, s), 
1.46 (9H, s), 1.33 (3H, d, J = 6.0 Hz). 
Rf = 0.25 (TLC, 20% EtOAc/hexane) for 3-15b; 1H NMR (CDCl3, 300 MHz): δ 5.91-
5.73 (1H, m), 5.17 (1H, t, J = 10.2 Hz), 4.30 (1H, m), 3.07-3.03 (1H, m), 1.45 (18H, s), 
1.23 (3H, d, J = 6.9 Hz); (ESI-MS): m/z  [M+Na]+ 338.0. 
 
 
Preparation of compound 3-22: To a solution of 3-21 (1.0 g, 8.4 mmol) in 
benzene (75 mL) were added pTSA (1.76 g, 9.24 mmol) and benzyl alcohol (11.8 mL, 
109.24 mmol) and then the reaction mixture was refluxed for 25 h. After evaporation 
of the solvent in vacuo, the residue was dissolved in EtOAc and the organic layer was 





over Na2SO4. The solvent was removed under reduced pressure to get the benzyl ester 
(800 mg) which was dissolved in THF (10 mL) and treated with benzyl chloroformate 
(0.58 mL, 4.0 mmol) in presence of Et3N (0.64 mL, 4.6 mmol) at 0 oC. The reaction 
mixture was then allowed to stir at rt for 1 h. THF was removed after completion of the 
reaction and the residue was then dissolved in EtOAc. The organic layer was washed 
with brine and dried over Na2SO4. The solvent was removed under reduced pressure to 
get the crude material which was purified by column chromatography over silica gel 
(25% EtOAc/hexane) to obtain pure 3-22 (1.0 g, 35% over two steps) as a white solid. 
Rf = 0.30 (TLC, 50% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 7.35 (10H, br), 
5.54 (1H, br), 5.23 (1H, d, J = 6.9 Hz), 5.19 (1H, d, J = 6.9 Hz), 5.13 (2H, s), 4.39-4.37 
(2H, m), 1.24 (3H, d, J = 6.3 Hz). 
 
Preparation of compound 3-23: To a solution of 3-22 (0.30 g, 0.88 mmol) in 
dry CH2Cl2 (5 mL) were added DIPEA (180 µL, 1.05 mmol) and MsCl (80 µL, 0.96 
mmol) at 0 oC and the reaction mixture was stirred for 1 h. As the reaction completed, 
it was extracted with EtOAc and the organic layer was washed with brine and dried 
over Na2SO4. The solvent was removed under reduced pressure to get the crude 
material which was purified by column chromatography over silica gel (15% 
EtOAc/hexane) to obtain pure 3-23 (300 mg, 85%) as a colourless oil. 
Rf = 0.4 (TLC, 70% Et2O/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.40-7.33 (10H, m), 
5.56 (1H, d, J = 9.5 Hz), 5.31-5.13 (5H, m), 4.62-4.58 (1H, m), 2.78 (3H, s), 1.48 (3H, 
d, J = 6.6 Hz); 13C NMR (CDCl3, 75 MHz): δ 168.93, 156.40, 135.85, 134.69, 128.79, 
128.71, 128.66, 128.54, 128.05, 78.01, 68.12, 67.43, 58.02, 38.22, 18.35; (ESI-MS): 






Preparation of compound 3-24: To a solution of 3-23 (0.30 g, 0.74 mmol) in 
anhydrous DMF (3 mL) was added NaCN (44 mg, 0.89 mmol) at 0 oC and the reaction 
mixture was stirred at rt for 12 h. As the reaction completed, it was extracted with Et2O 
and the organic layer was washed with brine and dried over Na2SO4. The solvent was 
removed under reduced pressure to get the crude material which was purified by 
column chromatography over silica gel (20% EtOAc/hexane) to obtain pure 3-24 (200 
mg, 77%) as a colourless oil. 
Rf = 0.5 (TLC, 50% EtOAc/hexane); IR (neat): vmax = 3331, 3036, 2952, 2248, 1960, 
1722, 1523, 1456, 1058, 744, 710 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.37-7.35 
(10H, m), 5.57-5.55 (1H, m), 5.27 (1H, d, J = 12.0 Hz), 5.23 (1H, d, J = 12.0 Hz), 5.14 
(2H, s), 4.63-4.61 (1H, m), 3.30 (1H, br), 1.33 (3H, d, J = 5.5 Hz); 13C NMR (CDCl3, 
125 MHz): δ 168.66, 156.11, 135.73, 134.46, 128.88, 128.77, 128.64, 128.62, 128.41, 
128.14, 119.10, 68.40, 67.65, 55.68, 29.61, 14.66; (ESI-MS): m/z [M+Na]+ 375.1. 
 
 
Preparation of compound 3-33: To a solution of ethyl glyoxylate (2.0 g, 
19.59 mmol) in dry DCM (20 mL) were added p-anisidine (2.41 g, 19.59 mmol) and 
4Å MS (4.5 g) at rt and the reaction mixture was allowed to stir for 3 h at that 
temperature. After completion of the reaction (checked by TLC), it was passed through 
a silica plug with a 15% EtOAc/hexane mixture to get the crude imine intermediate 





(739 mg, 6.42 mmol) in DMSO (42 mL) was added the crude imine slowly at 0 oC and 
the reaction mixture was stirred for 4 h at rt. Upon completion of the reaction (checked 
by TLC) half saturated NH4Cl solution was added at 0 oC and the reaction mixture was 
extracted with EtOAc. The organic layer was washed with brine and dried over 
Na2SO4. The solvent was removed under reduced pressure to get the crude material 
which was carefully purified over silica gel (15% EtOAc/hexane) to obtain 3-33 (3.3 g, 
65%, 99% ee,) as a brown oil. The enantiomeric excess was determined through HPLC 
analysis with Chiralpak column (0.46 cm ϕx25 cm) using hexanes/2-propanol (90:10) 
at a flow rate of 1.0 mL/min; detection UV 254 nm. 
Rf = 0.4 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 6.77 (2H, d, J = 
8.9 Hz), 6.64 (2H, d, J = 8.9 Hz), 4.31 (1H, br), 4.19-4.12 (2H, m), 3.86 (1H, br), 3.74 
(3H, s), 3.04-2.97 (1H, m), 2.22 (3H, s), 1.26-1.18 (6H, m). 














Preparation of compound 3-34: To a solution of compound 3-33 (565 mg, 
2.02 mmol) in dry THF (10 mL) was added Tebbe reagent (4.45 mL, 2.2 mmol) slowly 
at -78 oC and the reaction mixture was stirred at that temperature for 2 h and then 
slowly warmed up to rt and allowed to stir for 12 h. THF (5 mL) was added to the 
reaction mixture and then 2.5 mL of 5% NaOH solution was added at -15 oC. After 
stirring for 10 minute, it was warmed up to rt and filtered through short silica plug and 
washed with Et2O. The collected filtrate was extracted with Et2O and the organic layer 
was washed with brine and dried over Na2SO4. The solvent was removed under 
reduced pressure to get the crude material which was carefully purified over silica gel 
(7.5% EtOAc/hexane) to afford 3-34 (252 mg, 45%) as a yellow oil. 
Rf = 0.5 (TLC, 15% EtOAc/hexane); [α]D25 = -90.2 (c = 2.0, CHCl3); IR (thin film): 
vmax = 3373, 2979, 2832, 1729, 1516, 1369, 1241, 1182, 1036, 895, 821 cm-1; 1H NMR 
(CDCl3, 500 MHz): δ 6.76 (2H, d, J = 8.9 Hz), 6.60 (2H, d, J = 8.9 Hz), 4.82 (2H, s), 
4.15-4.07 (2H, m), 3.91 (1H, d, J = 7.6 Hz), 3.79 (1H, br), 3.73 (3H, s), 2.66-2.57 (1H, 
m), 1.78 (3H, s), 1.22-1.18 (6H, m); 13C NMR (CDCl3, 125 MHz): δ 173.71, 152.78, 
145.94, 141.41, 115.29, 114.83, 112.84, 61.69, 60.67, 55.70, 44.70, 19.52, 15.43, 







Preparation of compound 3-35: To a solution of ceric ammonium nitrate 
(CAN) (643.3 mg, 0.47 mmol) in H2O (10 mL) was added compound 3-34 (130 mg, 
1.2 mmol) in acetonitrile (5 mL) dropwise at 0 oC and the reaction mixture was stirred 
at that temperature for 45 minute. The reaction mixture was diluted with Et2O and 1M 
HCl (5 mL) was added and then it was extracted with Et2O. The aqueous layer was 
basified with sat. NaHCO3 solution and extracted with EtOAc. EtOAc layer was 
washed with brine and dried over Na2SO4. The solvent was removed under reduced 
pressure to get the crude material which was dissolved in Dioxane/H2O (3.0 mL/1.0 
mL). To this solution were added Et3N  (68 µL, 0.5 mmol) and (Boc)2O (142 µL, 0.62 
mmol) at 0 oC and the reaction mixture was stirred at rt for 12 h. The reaction mixture 
was extracted with EtOAc and the organic layer was washed with brine and dried over 
Na2SO4. The solvent was removed under reduced pressure to get the crude material 
which was purified over silica gel (7.5% EtOAc/hexane) to afford 3-35 (80 mg, 63%) 
as a colourless oil. 
Rf = 0.6 (TLC, 15% EtOAc/hexane); [α]D25 = +16.2 (c = 1.25, CHCl3); IR (thin film): 
vmax = 3360, 2979, 2935, 1720, 1504, 1367, 1344, 1249, 1165, 1027 cm-1; 1H NMR 
(CDCl3, 500 MHz): δ 4.98-4.89 (1H, br), 4.79 (2H, d, J = 18.0 Hz), 4.40-4.37 (1H, m), 
4.20-4.14 (2H, m), 2.58-2.55 (1H, m), 1.78 (3H, s), 1.43 (9H, s), 1.26 (3H, t, J = 7.6 
Hz), 1.05 (3H, d, J = 7.0 Hz); 13C NMR (CDCl3, 125 MHz): δ 172.29, 155.49, 145.56, 
112.46, 79.75, 61.05, 56.18, 43.87, 28.29, 20.13, 14.41, 14.16; HRMS (ESI): m/z calcd 










Preparation of compound 3-36: A suspension of 3-35 (5 mg, 0.02 mmol) in 1 
mL 6M HCl was refluxed for 24 h. The reaction mixture was basified with sat. 
NaHCO3 solution and then extracted with CHCl3 to obtain pure 3-36 (1.5 mg, 61%) as 
a colourless material. 
Rf = 0.3 (TLC, 20% MeOH/ CH2Cl2); 1H NMR (CDCl3, 500 MHz): δ 3.31 (1H, d, J = 
12.4 Hz), 1.99-1.92 (1H, m), 1.44 (3H, s), 1.26 (3H, s), 1.16 (3H, d, J = 6.9 Hz); 13C 
NMR (CDCl3, 125 MHz): δ 177.75, 84.36, 57.31, 48.97, 27.32, 22.01, 12.32; (ESI-
MS): m/z [M+H]+ 143.9. 




Preparation of compound 4-2: To a solution of compound 4-1 (6.0 g, 40.0 
mmol) in toluene (120 mL) were added benzyl alcohol (12.41 mL, 120.0 mmol) and 
TsOH (96 mg, 0.5 mmol) and then the reaction mixture was refluxed for 13 h. The 
solvent was removed under reduced pressure to get the crude material which was 
dissolved in Et2O and washed with sat. NaHCO3 solution. The organic layer was dried 
over Na2SO4 and removed in vacuo to obtain a viscous material. 5% Et2O/hexane was 
added to dissolve the residue and then cooled down to -20 oC.  A white solid was 
formed after 20 minute which was filtered to afford 4-2 (9.6 g, 73%) as a white solid 
(mp 52 oC) . 
Rf = 0.25 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.36 (10H, s), 








Preparation of compound 4-3: To a solution of compound 4-2 (1.0 g, 3.03 
mmol) in dry CH2Cl2 (3 mL) were added Et3N (0.64 mL, 4.55 mmol) and SOCl2 (264 
µL, 3.64 mmol) at 0 oC and the reaction mixture was stirred for 1 h. After completion 
of the reaction, the solvent was evaporated and the residue was extracted with Et2O. 
The organic layer was washed with brine and dried over Na2SO4. The solvent was 
removed under reduced pressure to get the crude material which was purified by 
column chromatography over silica gel (10% EtOAc/hexane) to obtain 4-3 (650 mg, 
57%) as a colourless oil. 
Rf = 0.45 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.39 (10H, s), 
5.77 (1H, d, J = 4.3 Hz), 5.30-5.26 (5H, m); (ESI-MS): m/z [M+Na]+ 399.0. 
 
 
Preparation of compound 4-4: To a solution of compound 4-3 (650 mg, 1.73 
mmol) in ACN (3 mL) were added RuCl3.XH2O (6.0 mg), NaIO4 (416 mg, 1.95 mmol) 
and H2O (4.5 mL) at 0 oC and the reaction mixture was stirred for 1 h. After 
completion of the reaction, the solvent was evaporated and the residue was extracted 
with Et2O. The organic layer was washed with brine and dried over Na2SO4. The 
solvent was removed under reduced pressure to obtain the crude material which was 
purified by column chromatography over silica gel (15% EtOAc/hexane) to obtain 4-4 





Rf = 0.4 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.42-7.41 (10H, 




Preparation of compound 4-5: To a solution of compound 4-4 (220 mg, 0.56 
mmol) in acetone/H2O (4.0 mL/1.0 mL) was added NaN3 (73 mg, 1.12 mmol) at 0 oC 
and the reaction mixture was allowed to stir for 1 h at rt. After consumption of the 
starting material (checked by TLC) acetone
 
was evaporated in vacuo and the residue 
was dissolved in Et2O. 20% H2SO4 (2.3 mL) was added carefully at 0 oC and the 
reaction mixture was allowed to stir for 12 h at rt. Et2O was used for extraction and the 
organic layer was washed with brine solution, dried over Na2SO4 and concentrated 
under reduced pressure to get the crude product which was purified over silica gel 
(20% EtOAc/hexane) to obtain 4-5 (156 mg, 79%) as a colourless oil. 
 Rf = 0.5 (TLC, 25% EtOAc/hexane); IR (neat): vmax = 3481, 2115, 1749, 1735, 1267, 
1213, 1111, 696 cm-1; 1H NMR (CDCl3, 300 MHz): δ 7.35-7.29 (10H, m), 5.15-5.02 
(4H, m), 4.70-4.67 (1H, m), 4.36 (1H, d, J = 2.6 Hz ), 3.26 (1H, d, J = 4.9 Hz); (ESI-
MS): m/z [M+Na]+ 378.1. 
 
Preparation of compound 4-8: To a solution of compound 4-5 (300 mg, 0.85 
mmol) in THF (10 mL) were added PPh3 (444 mg, 1.69 mmol) and H2O (100 µL) and 
then the reaction mixture was refluxed for 6 h. The solvent was removed under 





mL/3 mL). To this mixture were added Et3N (173 µL, 1.21 mmol) and (Boc)2O (174 
µL, 0.76 mmol) at 0 oC and the reaction mixture was stirred the reaction mixture for 12 
h at rt. The reaction mixture was extracted with EtOAc and the organic layer was 
washed with brine and dried over Na2SO4. The solvent was removed under reduced 
pressure to get the crude material which was purified over silica gel (20% 
EtOAc/hexane) to afford 4-8 (242 mg, 67% over two steps) as a colourless oil. 
Rf = 0.35 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.36-7.23 (10H, 
m), 5.47 (1H, d, J = 7.6 Hz), 5.11-4.85 (5H, m), 4.55 (1H, s), 1.43 (9H, s); 13C NMR 
(CDCl3, 75 MHz): δ 171.44, 168.62, 155.73, 134.80, 134.72, 128.86, 128.79, 128.74, 





Preparation of compound 4-11: To a solution of compound 4-10 (1.4 g, 18.92 
mmol) in DMF (20 mL) were added imidazole (1.8 g, 26.5 mmol), DMAP (116 mg, 
0.95 mmol) and TBSCl (4.3 mL, 24.6 mmol) at 0 oC and the reaction mixture was 
stirred at rt for 12 h. After completion of the reaction, H2O (100 mL) was added and 
the reaction mixture was extracted with Et2O. The organic layer was washed with brine 
and dried over Na2SO4. The solvent was removed under reduced pressure to get the 
crude material which was purified over silica gel (2% EtOAc/hexane) to afford 4-11 
(2.15 g, 60%) as a colourless oil. 
Rf = 0.5 (TLC, 5% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 4.12 (2H, s), 2.14 








Preparation of compound 4-12: To a suspension of NaH (244.6 mg, 10.2 mmol) 
(washed with hexane prior to the reaction) in dry THF (20 mL) was added triethyl 
phosphonoacetate (2.0 g, 8.95 mmol) in dry THF (10 mL) slowly at 0 oC and after 
complete addition, the mixture was allowed to stir for 1 h at rt. To this reaction flask 
compound 4-11 (1.37 g, 7.28 mmol) in 5 mL dry THF was added slowly at 0 oC and 
the reaction mixture was stirred for 20 h at rt. The reaction was quenched by careful 
dropwise addition of H2O at 0 oC until a clear solution appeared and then it was 
extracted with Et2O twice. Combined extract was washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to get the crude mixture. Careful 
purification (0.5% to 1.5% EtOAc/hexane) over silica gel column chromatography 
afforded 4-12 (1.6 g, 85%, E/Z = 2.3:1) as a colourless oil.  
Rf = 0.7 (TLC, 5% Et2O/hexane); 1H NMR (CDCl3, 500 MHz): δ 5.97 (1H, d, J = 1.9 
Hz), 4.17-4.11 (2H, m), 4.09 (2H, d, J = 1.3 Hz), 2.03 (3H, s), 1.27 (3H, t, J = 7.0 Hz), 
0.90 (9H, s), 0.07 (6H, s). 
 
Preparation of compound 4-13: To a solution of compound 4-12 (160 mg, 
0.62 mmol) in tBuOH/H2O (1:1, 6 mL) were added AD-mix β (870 mg, 1.4 g/mmol) 
and methanesulfonamide (62 mg, 100 mg/mmol)  at -1 oC and the reaction mixture 
was allowed to stir for 96 h at that temperature. The reaction was quenched by addition 
of Na2SO3 (918 mg, 1.48 mg/mmol) and stirred for 1 h at rt until it became colourless. 





over Na2SO4 and concentrated under reduced pressure to get the crude product which 
was purified over silica gel (15% EtOAc/hexane)  to obtain pure 4-13 (154 mg, 85%) 
as a colourless oil. 
Rf = 0.25 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 4.27-4.16 (2H, 
m), 4.05 (1H, s), 3.67 (1H, d, J = 9.7 Hz), 3.47 (1H, d, J = 9.7 Hz), 3.34 (1H, br), 3.11 
(1H, br), 1.30 (3H, t, J = 7.2 Hz), 1.19 (3H, s), 0.88 (9H, s), 0.05 (6H, s); 13C NMR 
(CDCl3, 75 MHz): δ 173.11, 73.96, 73.86, 67.38, 61.69, 25.81, 21.17, 18.32, 14.09, -








Preparation of compound 4-14: To a solution of compound 4-13 (400 mg, 
1.37 mmol) in CH2Cl2 (10 mL) were added Et3N (384 µL, 2.74 mmol) and SOCl2 (200 
µL, 2.74 mmol) carefully at 0 oC and the reaction mixture was allowed to stir for 30 
minute at that temperature. After consumption of the starting material (checked by 
TLC), CH2Cl2 was evaporated in vacuo and the cyclic sulphite was eluted through 
silica plug with Et2O. The organic layer was washed with brine, dried over Na2SO4 and 
concentrated at reduced pressure to obtain the crude product which was dissolved in 
CH3CN (10 mL). To this solution were added RuCl3 (2 mg), NaIO4 (440 mg, 2.06 
mmol) and H2O (15 mL) at 0 oC and the reaction mixture was allowed to stir for 30 
minute at that temperature. The reaction mixture was diluted with Et2O and extracted. 
The organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude product which was purified over silica gel (10% 





Rf = 0.35 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 5.43 (1H, s), 
4.36 (2H, q, J = 7.2 Hz), 3.91 (1H, d, J = 12.0 Hz), 3.80 (1H, d, J = 12.0 Hz), 1.56 
(3H, s), 1.35 (3H, t, J = 7.1 Hz), 0.92 (9H, s), 0.12 (3H, s), 0.11 (3H, s); 13C NMR 
(CDCl3, 75 MHz): δ 164.08, 92.99, 78.87, 65.02, 62.89, 25.66, 18.21, 17.72, 14.05, -
5.44, -5.67; (ESI-MS): m/z [M+Na]+ 377.0, [M-H]- 353.4.  
 
Preparation of compound 4-15: To a solution of compound 4-14 (250 mg, 
0.70 mmol) in acetone/H2O (8 mL/ 2 mL) was added NaN3 (230 mg, 3.5 mmol) and 
the reaction mixture was heated at 50 oC for 8 h. After consumption of the starting 
material (checked by TLC), acetone
 
was evaporated in vacuo and the residue was 
dissolved in Et2O. 20% H2SO4 (3 mL) was added carefully at 0 oC and the reaction 
mixture was allowed to stir for 12 h at rt. Et2O was used for extraction and the organic 
layer was washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure to get the crude product which was purified over silica gel (5% 
EtOAc/hexane) to afford 4-15 (168 mg, 70%) as a colourless oil. 
Rf = 0.5 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 4.37-4.25 (2H, 
m), 3.98 (1H, s), 3.64 (1H, d, J = 10.2 Hz), 3.42 (1H, d, J = 10.2 Hz), 3.10 (1H, s), 
1.33 (3H, t, J = 7.2 Hz), 1.21 (3H, s), 0.91 (9H, s), 0.09 (6H, s); 13C NMR (CDCl3, 75 
MHz): δ 169.28, 74.59, 67.85, 65.11, 61.85, 25.82, 19.80, 18.29, 14.15, -5.49, -5.54; 
(ESI-MS): m/z [M+Na]+ 340.1. 
 
 
Preparation of compound 4-16: To a solution of compound 4-15 (55 mg, 0.17 
mmol) in MeOH
 





stirred over night under hydrogen atmosphere. The amine was eluted with MeOH 
through a celite pad. To a solution of the crude amine in THF (2 mL) were added Et3N 
(26 µL, 0.19 mmol) and CbzCl (23 µL, 0.16 mmol) at 0 oC and the reaction mixture 
was allowed to stir for 1 h at rt. After completion of the reaction, it was extracted with 
EtOAc and the organic layer was washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure to get the crude product which was purified over 
silica gel (15% EtOAc/hexane) to afford 4-16 (51 mg, 70% over two steps) as a 
colourless oil. 
Rf = 0.3 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.35-7.30 (5H, 
m), 5.80 (1H, br), 5.12-5.07 (2H, m), 4.38-4.18 (3H, m), 3.66 (1H, d, J = 10.0 Hz), 
3.43 (1H, d, J = 10.0 Hz), 1.17 (3H, s), 0.91 (9H, s), 0.06 (6H, s); 13C NMR (CDCl3, 
75 MHz): δ 171.09, 156.00, 136.24, 128.46, 128.09, 127.95, 72.94, 68.24, 67.03, 
61.37, 59.74, 25.80, 21.44, 18.21, 14.04, -5.60, -5.65; (ESI-MS): m/z [M+Na]+ 448.2. 
  
 
Preparation of compound 4-19: To a solution of compound 4-12 (50 mg, 0.19 
mmol) in dry THF
 
(2 mL) was added TBAF (200 µL, 0.22 mmol) at 0 oC and the 
reaction mixture was stirred for 30 minute. The reaction mixture was concentrated 
under reduced pressure to get the crude product which was purified over silica gel (8% 
EtOAc/hexane) to afford 4-19 (20 mg, 71%) as a colourless oil.  
Rf = 0.3 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 5.97-5.96 (1H, 
m), 4.18-4.12 (4H, m), 2.07 (3H, s), 1.27 (3H, t, J = 6.9 Hz); 13C NMR (CDCl3, 125 









Preparation of compound 4-20: To a solution of compound 4-19 (20 mg, 0.14 
mmol) in acetone/H2O (1 mL/ 0.1 mL) was added CrO3 (32 mg, 0.32 mmol) at 0 oC 
and the reaction mixture was stirred for 90 minute. The reaction mixture was 
concentrated under reduced pressure to get the crude product which was purified over 
silica gel (30% EtOAc/hexane) to afford 4-20 (20 mg, quantitative) as a colourless oil.  
Rf = 0.35 (TLC, 50% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 9.13 (1H, br), 
6.89 (1H, d, J = 1.3 Hz), 4.24 (2H, q, J = 7.2 Hz), 2.28 (3H, s), 1.32 (3H, t, J = 7.2 




Preparation of compound 4-21: To a solution of 4-20 (20 mg, 0.13 mmol) in 
CH2Cl2 (1 mL) were added DCC (32 mg, 0.15 mmol), BnOH (15 µL, 0.14 mmol) and 
DMAP (1.5 mg, 0.01 mmol) at 0 oC and the reaction mixture was stirred the reaction 
mixture for 12 h at rt. After completion of the reaction, it was extracted with Et2O and 
the organic layer was washed with brine and dried over Na2SO4. The solvent was 
removed under reduced pressure to get the crude material which was purified by 
column chromatography over silica gel (4.0% EtOAc/hexane) to obtain pure 4-21 (25 
mg, 80%) as a colourless oil. 
Rf = 0.6 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.39-7.36 (5H, 





1.30 (3H, t, J = 7.2 Hz); 13C NMR (CDCl3, 75 MHz): δ 166.95, 165.83, 143.34, 
135.46, 128.62, 128.41, 128.23, 127.13, 67.27, 60.64, 14.30, 14.14. 
 
 
Preparation of compound 4-23: To a solution of compound 4-21 (50 mg, 0.20 
mmol) in tBuOH/H2O (1:1, 3 mL) were added AD-mix β (280 mg, 1.4 g/mmol) and 
methanesulfonamide (20 mg, 100 mg/mmol)  at -1 oC and the reaction mixture was 
allowed to stir for 48 h at that temperature. The reaction was quenched by addition of 
Na2SO3 (300 mg, 1.48 mg/mmol) and stirred for 1 h at rt until it became colourless. 
CH2Cl2 was used for extraction and the organic layer was washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure to get the crude product which 
was purified over silica gel (25% EtOAc/hexane)  to obtain pure 4-23 (47 mg, 83%) as 
a colourless oil. 
Rf = 0.25 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.39-7.33 (5H, 
m), 5.25 (2H, d, J = 1.8 Hz), 4.36-4.25 (3H, m), 3.66 (1H, br), 3.40 (1H, br), 1.53 (3H, 
s), 1.31 (3H, t, J = 7.2 Hz ); 13C NMR (CDCl3, 75 MHz): δ 174.14, 171.17, 135.02, 
128.61, 128.50, 128.12, 76.93, 75.02, 68.01, 62.20, 21.87, 14.11; (ESI-MS): m/z 
[M+Na]+ 305.1. 
 
Preparation of compound 4-25: To a solution of compound 4-23 (50 mg, 0.18 
mmol) in CH2Cl2 (1 mL) were added Et3N (50 µL, 0.36 mmol) and SOCl2 (26 µL, 0.36 





that temperature. After consumption of the starting material (checked by TLC), 
CH2Cl2 was evaporated in vacuo and the cyclic sulphite was eluted through silica plug 
with Et2O. The organic layer was washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure to obtain the crude product which was dissolved 
in CH3CN (1 mL). To this solution were added RuCl3 (1 mg), NaIO4 (54 mg, 0.25 
mmol) and H2O (1.5 mL) at 0 oC and the reaction mixture was allowed to stir for 30 
minute at that temperature. The reaction mixture was diluted with Et2O and extracted. 
The organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude product which was purified over silica gel (10% 
EtOAc/hexane) to afford 4-25 (24 mg, 37% over two steps) as a colourless oil. 
Rf = 0.4 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.41-7.37 (5H, 
m), 5.68 (1H, s), 5.32 (2H, s), 4.33 (2H, q, J = 7.2 Hz), 1.73 (3H, s), 1.31 (3H, t, J = 
7.2 Hz ); 13C NMR (CDCl3, 75 MHz): δ 166.31, 163.20, 133.94, 128.98, 128.76, 
128.43, 86.92, 80.55, 69.32, 63.29, 19.15, 13.95; (ESI-MS): m/z [M+Na]+ 367.0. 
 
 
Preparation of compound 4-26: To a solution of compound 4-25 (50 mg, 0.15 
mmol) in acetone/H2O (4 mL/1 mL) was added NaN3 (48 mg, 0.75 mmol) and the 
reaction mixture was heated at 50 oC for 4 h. After consumption of the starting 
material (checked by TLC), acetone
 
was evaporated in vacuo and the residue was 
dissolved in Et2O. 20% H2SO4 (1 mL) was added carefully at 0 oC and the reaction 
mixture was allowed to stir for 12 h at rt. Et2O was used for extraction and the organic 





pressure to get the crude product which was purified over silica gel (10% 
EtOAc/hexane) to afford 4-26 (31 mg, 70%) as a colourless oil. 
Rf = 0.3 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.38 (5H, s), 5.23 
(2H, s), 4.51 (1H, s), 4.22-4.07 (2H, m), 3.18 (1H, br), 1.69 (3H, s), 1.22 (3H, t, J = 7.2 
Hz ); 13C NMR (CDCl3, 75 MHz): δ 171.09, 170.37, 134.88, 128.64, 128.61, 128.40, 
73.82, 68.86, 67.86, 62.68, 19.64, 13.87; (ESI-MS): m/z [M+NH4]+ 325.0, [M+Na]+ 
330.0 
 
Preparation of compound 4-28: To a solution of cyclic sulphate of benzyl 
protected analogue of 4-14 (1.25 g, 3.79 mmol) in acetone/H2O (100 mL/25 mL) was 
added NaN3 (1.43 g, 22 mmol) and the reaction mixture was heated at 50 oC for 7 h. 
After consumption of the starting material (checked by TLC), acetone
 
was evaporated 
in vacuo and the residue was dissolved in Et2O. 20% H2SO4 (16 mL) was added 
carefully at 0 oC and the reaction mixture was allowed to stir for 12 h at rt. Et2O was 
used for extraction and the organic layer was washed with brine, dried over Na2SO4 
and concentrated under reduced pressure to get the crude product which was purified 
over silica gel (7% EtOAc/hexane) to afford 4-28 (800 mg, 73%) as a colourless oil. 
Rf = 0.4 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.39-7.28 (5H, 
m), 4.58 (1H, d, J = 11.9 Hz), 4.53 (1H, d, J = 11.9 Hz), 4.27-4.16 (2H, m), 4.04 (1H, 
s), 3.52 (1H, d, J = 9.6 Hz), 3.36 (1H, d, J = 9.6 Hz), 3.27 (1H, s), 1.31-1.24 (6H, m); 
13C NMR (CDCl3, 75 MHz): δ 169.30, 137.48, 128.41, 127.86, 127.75, 74.55, 74.31, 








Preparation of compound 4-30: To a solution of compound 4-28 (60 mg, 0.20 
mmol) in THF
 
(2 mL) was added 10% Pd/C (12 mg) and the reaction mixture was 
stirred under hydrogen atmosphere for 4 h. The amine was eluted with MeOH through 
a celite pad. The solvent was concentrated under reduced pressure to get the crude 
product which was purified over silica gel (15% MeOH/CH2Cl2) to afford 4-30 (54 
mg, quantitative) as a brown oil. 
Rf = 0.2 (TLC, 20% MeOH/CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 7.29-7.19 (5H, 
m), 4.44 (1H, d, J = 12.0 Hz), 4.39 (1H, d, J = 12.0 Hz), 4.09-3.98 (2H, m), 3.40-3.37 
(2H, m), 3.25 (1H, d, J = 9.4 Hz), 1.21 (3H, s), 1.15 (3H, t, J = 7.2 Hz); 13C NMR 
(CDCl3, 125 MHz): δ 174.05, 137.96, 128.39, 128.31, 127.79, 127.67, 127.64, 75.07, 
73.51, 72.71, 61.01, 60.11, 21.63, 14.07; (ESI-MS): m/z [M+H]+ 268.1, [M+Na]+ 
290.1. 
 
Preparation of compound 4-31: To a solution of compound 4-30 (20 mg, 0.08 
mmol) in Dioxane/H2O (0.5 mL/0.2 mL) were added NaHCO3 (10 mg, 0.11 mmol) 
and FmocCl (20 mg, 0.08 mmol) at 0 oC and the reaction mixture was stirred at rt for 
12 h. The reaction mixture was extracted with EtOAc and the organic layer was 
washed with brine and dried over Na2SO4. The solvent was removed under reduced 
pressure to get the crude material which was purified over silica gel (25% 





Rf = 0.2 (TLC, 50% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.76 (2H, d, J = 
7.6 Hz), 7.58 (2H, d, J = 7.6 Hz), 7.43-7.28 (10H, m), 5.80 (1H, br), 4.54 (2H, d, J = 
4.3 Hz), 4.41-4.39 (3H, m), 4.25-4.05 (3H, m), 3.55 (1H, d, J = 9.4 Hz), 3.40 (1H, d, J 




Preparation of compound 4-38: To a solution of compound 4-28 (250 mg, 0.68 
mmol) in dry THF (5 mL) was added LiBH4 (30 mg, 1.36 mmol) portionwise at 0 oC 
and the reaction mixture was allowed to stir for 7 h. After complete consumption of the 
starting material MeOH was added slowly at 0 oC until a clear solution was formed 
and then the solvent was evaporated to get the crude material. 1M HCl was added to 
the crude viscous material and then extracted with EtOAc. The organic layer was dried 
over Na2SO4, concentrated under reduced pressure to get the crude product which was 
purified over silica gel (20% EtOAc/hexane) to afford pure 4-38 (180 mg, 84%) as a 
colourless oil. 
Rf = 0.2 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.39-7.32 (5H, 
m), 4.58 (2H, s), 4.01-3.96 (1H, m), 3.79-3.68 (2H, m), 3.55 (1H, d, J = 9.4 Hz), 3.33 
(1H, d, J = 9.4 Hz), 2.81 (1H, br), 2.45 (1H, br), 1.14 (3H, s); 13C NMR (CDCl3, 75 
MHz): δ 137.32, 128.48, 127.97, 127.85, 74.90, 74.17, 73.51, 66.88, 61.96, 19.71; 
(ESI-MS): m/z [M+Na]+ 274.1. 
 
Preparation of compound 4-40: To a solution of compound 4-38 (18 mg, 0.07 





TBDPSCl (25 µL, 0.09 mmol) at 0 oC and the reaction mixture was stirred at rt for 12 
h. After completion of the reaction, H2O (10 mL) was added and the reaction mixture 
was extracted with Et2O. The organic layer was washed with brine and dried over 
Na2SO4. The solvent was removed under reduced pressure to get the crude material 
which was purified over silica gel (7% EtOAc/hexane) to afford 4-40 (28 mg, 80%) as 
a colourless oil. 
Rf = 0.4 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.64-7.59 (5H, 
m), 7.36-7.17 (10H, m), 4.42 (2H, s), 3.99-3.95 (1H, dd, J = 10.5, 3.2 Hz), 3.78-3.72 
(1H, dd, J = 10.6, 8.3 Hz), 3.63-3.59 (1H, dd, J = 8.4, 3.0 Hz), 3.41 (1H, d, J = 9.2 






Preparation of compound 4-42: To a solution of hydroxyacetone (100 mg, 1.35 
mmol) and 2-PMBO-lepidine or Dudley’s reagent (764 mg, 2.70 mmol) in 
trifluorotoluene (10 mL) was added dried MgO (109 mg, 2.7 mmol) and then the 
reaction mixture was cooled to 0 oC. To this cold solution was added methyl triflate 
(308 µL, 2.7 mmol) slowly and the reaction mixture was warmed to rt and allowed to 
stir for 12 h at that temperature. After completion of the reaction, it was diluted with 
EtOAc and decanted away from MgO. The collected organic layer was washed with 
brine and dried over Na2SO4. The solvent was removed under reduced pressure to get 
the crude material which was purified over silica gel (4% EtOAc/hexane) to afford 4-
42 (196 mg, 75%) as a colourless oil. 
Rf = 0.3 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.32-7.29 (2H, 





(3H, s), 2.17 (3H, s); 13C NMR (CDCl3, 75 MHz): δ 206.68, 159.40, 129.49, 129.13, 
113.81, 74.88, 72.85, 55.16, 26.30. 
 
Preparation of compound 4-43: To the suspension of NaH (35 mg, 1.44 mmol) 
(washed with Hexane prior to the reaction) in dry THF was added triethyl 
phosphonoacetate slowly (0.25 mL, 1.24 mmol) at 0 oC and after complete addition, 
the reaction mixture was allowed to stirred for 1 h at rt. To this reaction flask 
compound 4-42 (196 mg, 1.0 mmol) was added slowly at 0 oC and stirred for 20 h at rt. 
The reaction was quenched by very careful dropwise addition of water at 0 oC until a 
clear solution appeared and then it was extracted with Et2O twice. The combined 
organic extract was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude mixture. Careful purification over silica gel column 
chromatography (0.5% to 1.5% EtOAc/hexane) produced 4-43 (203 mg, 75%, E/Z = 
3:1) as a colourless oil.  
(E)-isomer: 
Rf = 0.6 (TLC, 5% Et2O/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.27 (2H, d, J = 6.9 
Hz), 6.89 (2H, d, J = 6.9 Hz), 5.99 (1H, s), 4.46 (2H, s), 4.17 (2H, q, J = 7.6 Hz), 3.96 
(2H, s), 3.81 (3H, s), 2.10 (3H, s), 1.28 (3H, t, J = 7.6 Hz); 13C NMR (CDCl3, 75 
MHz): δ 166.70, 159.32, 154.61, 129.87, 129.30, 115.27, 113.86, 73.83, 72.19, 59.67, 
55.27, 15.85, 14.3. 
 (Z)-isomer: 
Rf = 0.65 (TLC, 5% EtOAc/hexane);  1H NMR (CDCl3, 500 MHz): δ 7.26 (2H, d, J = 
8.2 Hz), 6.87 (2H, d, J = 8.2 Hz), 5.75 (1H, s), 4.62 (2H, s), 4.44 (2H, s), 4.12 (2H, q, J 





MHz): δ 165.93, 159.18, 157.03, 130.36, 129.65, 129.26, 117.24, 113.75, 72.34, 69.01, 
59.77, 55.23, 21.69, 14.23.  
 
Preparation of compound 4-44: To a solution of compound 4-43 (80 mg, 0.30 mmol) 
in tBuOH/H2O (1:1, 8 mL) were added AD-mix β (420 mg, 1.4 g/mmol) and 
methanesulfonamide (30 mg, 100 mg/mmol)  at -1 oC and the reaction mixture was 
allowed to stir for 72 h at that temperature. The reaction was quenched by addition of 
Na2SO3 (444 mg, 1.48 mg/mmol) and stirred for 1 h at rt until it became colourless. 
CH2Cl2 was used for extraction and the organic layer was washed with 2M NaOH, 
brine solution, dried over Na2SO4 and concentrated under reduced pressure to get the 
crude product which was purified over silica gel (20% EtOAc/hexane) to afford 4-44 
(75 mg, 83%) as a colourless oil. 
Rf = 0.35 (TLC, 25% EtOAc/hexane); [α]D24 = +19.5 (c = 1.4, CHCl3); 1H NMR 
(CDCl3, 500 MHz): δ 7.22 (2H, d, J = 8.8 Hz), 6.86 (2H, d, J = 8.2 Hz), 4.40 (2H, d, J 
= 5.1 Hz), 4.12-4.10 (1H, m), 4.05-4.03 (2H, m), 3.78 (3H, s), 3.53 (2H, d, J = 9.5 Hz), 
3.40 (1H, s), 3.35 (1H, d, J = 9.5 Hz), 1.23 (3H, s), 1.18 (3H, t, J = 7.0 Hz); 13C NMR 
(CDCl3, 125 MHz): δ 173.15, 159.08, 129.35, 113.48, 73.86, 73.70, 73.26, 73.02, 
61.57, 54.99, 21.53, 13.77; (ESI-MS): m/z [M+Na]+ 321.1. 
 
 
Preparation of compound 4-46: To a solution of compound 4-45 (1.1 g, 3.0 
mmol) in acetone/H2O (100 mL/25 mL) was added NaN3 (1.4 g, 21.6 mmol) and the 





material (checked by TLC), acetone
 
was evaporated in vacuo and the residue was 
dissolved in Et2O. 20% H2SO4 (15 mL) was added carefully at 0 oC and the reaction 
mixture was allowed to stir for 12 h at rt. Et2O was used for extraction and the organic 
layer was washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure to get the crude product which was purified over silica gel (15% 
EtOAc/hexane) to afford 4-46 (690 mg, 70%) as a colourless oil. 
Rf = 0.5 (TLC, 25% EtOAc/hexane);  1H NMR (CDCl3, 300 MHz): δ 7.24 (2H, d, J = 
8.6 Hz), 6.89 (2H, d, J = 8.6 Hz), 4.50 (1H, d, J = 11.5 Hz), 4.45 (1H, d, J = 11.5 Hz), 
4.26-4.15 (2H, m), 4.02 (1H, s), 3.81 (3H, s), 3.47 (1H, d, J = 9.6 Hz), 3.33 (1H, d, J = 
9.6 Hz), 3.25 (1H, s), 1.29 (3H, t, J = 7.2 Hz), 1.23 (3H, s); 13C NMR (CDCl3, 75 
MHz): δ 169.30, 159.35, 129.55, 129.41, 113.79, 74.27, 74.19, 73.16, 65.40, 61.85, 
55.22, 20.53, 14.04. 
 
 
Preparation of compound 4-47: To a solution of compound 4-44 (100 mg, 
0.34 mmol) in dry THF (1.5 mL) was added LiBH4 (11.6 mg, 0.51 mmol) portionwise 
at 0 oC and the reaction mixture was allowed to stir for 1h. After complete 
consumption of the starting material MeOH was added slowly at 0 oC until a clear 
solution appeared and then it was evaporated to get the crude material. 1M HCl was 
added to the viscous material and it was extracted with EtOAc. The organic layer was 
dried over Na2SO4 and concentrated under reduced pressure to get the crude product 
which was purified over silica gel (40% EtOAc/hexane) to afford 4-47 (75 mg, 87%) 
as a colourless oil. 
Rf = 0.3 (TLC, 50% EtOAc/hexane); [α]D24 = +23.4 (c = 0.9, CHCl3); 1H NMR 





= 11.7 Hz), 4.44 (2H, d, J = 11.7 Hz),  3.78 (3H, s), 3.72-3.64 (4H, m), 3.43 (2H, d, J 
= 9.0 Hz), 3.38 (2H, d, J = 9.0 Hz), 3.27 (1H, s), 1.14 (3H, s); 13C NMR (CDCl3, 75 
MHz): δ 159.35, 129.39, 113.86, 75.75, 74.82, 73.35, 73.33, 62.72, 55.21, 21.00; (ESI-
MS): m/z [M+Na]+ 279.1, [M-H]- 255.1. 
 
Preparation of compound 4-48: To an ethanolic (2 mL) solution of compound 
4-47 (50 mg, 0.20 mmol) was added 10% Pd-C (15 mg) carefully under argon 
atmosphere. The reaction mixture was connected to vacuum to remove oxygen from 
the flask and purged with H2 gas. The reaction mixture was allowed to stir for 10 h 
under H2 atmosphere (1 atm.) at rt. The reaction mixture was filtered through celite 
and washed with EtOH. The solvent was evaporated to dryness and then chloroform 
was added to dissolve the impurity and decanted away to afford 4-48 (26 mg, 
quantitative) as a viscous material. 
Rf = 0.2 (TLC, EtOAc); [α]D24 = +9.0 (c = 1.1, MeOH); 1H NMR (CD3OD, 300 MHz): 
δ 3.74 (1H, m), 3.62-3.44 (4H, m), 1.16 (3H, s); 13C NMR (CD3OD, 75 MHz): δ 76.70, 
74.90, 68.11, 63.68, 21.35; (ESI-MS): m/z [M+Na]+ 159.0, [M-H]- 135.1. 
 
 
Preparation of compound 4-53: To a solution of compound 4-46 (15 mg, 0.05 
mmol) in CH2Cl2/H2O (1 mL/ 0.1 mL) was added DDQ (13 mg, 0.06 mmol) at 0 oC 





reaction, it was directly transferred into silica gel column and purified with 15% 
EtOAc/hexane to obtain 4-53 (8 mg, 50%) as a colourless oil. 
Rf = 0.3 (TLC, 25% EtOAc/hexane);  1H NMR (CDCl3, 500 MHz): δ 8.00 (2H, d, J = 
9.0 Hz), 6.93 (2H, d, J = 9.0 Hz), 4.34-4.22 (4H, m), 4.05 (1H, s), 3.87 (3H, s), 3.41 
(1H, s), 1.38 (3H, s), 1.30 (3H, t, J = 7.0 Hz); (ESI-MS): m/z [M+Na]+ 360.2. 
 
 
Preparation of compound 4-54: To a solution of compound 4-46 (300 mg, 
0.93 mmol) in THF
 
(5 mL) was added 10% Pd/C (90 mg) and the reaction mixture was 
stirred under hydrogen atmosphere (1 atm.) for 4 h. The amine was eluted with MeOH 
through celite pad. To a solution of the crude amine in Et2O/H2O (3 mL/3 mL) were 
added K2CO3 (150 mg, 1.1 mmol) and CbZCl (160 µL, 1.1 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 12 h at rt. After completion of the reaction, it 
was extracted with EtOAc. The organic layer was washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to get the crude product which was 
purified over silica gel (15% EtOAc/hexane) to afford 4-54 (305 mg, 76% over two 
steps) as a colourless oil. 
Rf = 0.4(TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 7.35-7.32 (5H, m), 
7.23 (2H, d, J = 8.5 Hz), 6.88-6.85 (2H, m), 5.79 (1H, d, J = 9.0 Hz), 5.11 (2H, s), 
4.45-4.35 (3H, m), 4.13-4.06 (2H, m), 3.80 (3H, s), 3.49 (1H, d, J = 9.5 Hz), 3.33 (1H, 
d, J = 9.5 Hz), 3.09 (1H, s), 1.25-1.21 (6H, m); 13C NMR (CDCl3, 75 MHz): δ 170.94, 
159.26, 136.15, 129.41, 129.25, 128.40, 128.05, 127.94, 113.73, 74.54, 73.15, 72.81, 







Preparation of compound 4-55: To a solution of compound 4-54 (60 mg, 0.14 
mmol) in dry THF (1.5 mL) was added LiBH4 (5 mg, 0.21 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 5 h. After complete consumption of the 
starting material MeOH was added slowly at 0 oC until a clear solution appeared and 
then it was evaporated to get the crude material. 1M HCl was added to the viscous 
material and then extracted with EtOAc. The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure to get the crude product which was purified over 
silica gel (40% EtOAc/hexane) to afford 4-55 (38 mg, 70%) as a colourless oil. 
Rf = 0.2 (TLC, 60% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 7.37-7.29 (5H, 
m), 7.22 (2H, d, J = 8.5 Hz), 6.87 (2H, d, J = 8.5 Hz), 5.74 (1H, d, J = 8.2 Hz), 5.10 
(2H, s), 4.46 (2H, s), 3.83-3.79 (4H, m), 3.73-3.68 (2H, m), 3.43-3.37 (2H, m), 3.14 
(1H, br), 1.23 (3H, s); 13C NMR (CDCl3, 125 MHz): δ 159.39, 157.19, 136.27, 129.42, 
129.28, 128.46, 128.09, 127.99, 113.87, 74.56, 74.31, 73.32, 66.95, 62.61, 57.57, 




Preparation of compound 4-56: To a solution of compound 4-55 (20 mg, 0.05 
mmol) in ACN/H2O (1 mL/0.1 mL) was added CAN (55 mg, 0.1 mmol) at 0 oC and 
the reaction mixture was allowed to stir for 1 h. After complete consumption of the 
starting material, it was extracted with EtOAc. The organic layer was dried over 





purified over silica gel (80% EtOAc/hexane) to afford 4-56 (10 mg, 72%) as a 
colourless oil. 
Rf = 0.2 (TLC, EtOAc); 1H NMR (CDCl3, 500 MHz): δ 7.37-7.33 (5H, m), 5.41 (1H, 
d, J = 8.8 Hz), 5.11 (2H, s), 3.88-3.86 (2H, m), 3.74-3.70 (1H, m), 3.59 (1H, d, J = 
12.0 Hz), 3.31 (1H, d, J = 12.0 Hz), 3.15 (1H, br), 2.70 (1H, br), 1.14 (3H, s); 13C 
NMR (CDCl3, 125 MHz): δ 157.70, 135.97, 128.58, 128.31, 128.09, 74.51, 67.55, 
67.36, 61.55, 56.05, 20.05; (ESI-MS): m/z [M-H]- 267.9. 
 
Preparation of compound 4-58: To a solution of compound 4-46 (90 mg, 0.28 
mmol) in THF/H2O (2 mL/2 mL) was added LiOH (10 mg, 0.42 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 2 h at that temperature. After completion of the 
reaction (checked by TLC), it was extracted with Et2O. The aqueous layer was 
acidified with 10% NaHSO4 to pH 2-3 and then extracted with EtOAc. The organic 
layer was washed with brine and dried over Na2SO4. The solvent was removed under 
reduced pressure to obtain 4-58 (50 mg, 62%) as a colourless oil. 
Rf = 0.25 (TLC, 15% MeOH/CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 7.26 (2H, d, J = 
8.6 Hz), 6.89 (2H, d, J = 8.6 Hz), 6.24 (2H, br), 4.53 (1H, d, J = 11.4 Hz), 4.48 (1H, d, 
J = 11.4 Hz), 4.19 (1H, s), 3.80 (3H, s), 3.54 (1H, d, J = 9.6 Hz), 3.32 (1H, d, J = 9.6 
Hz), 1.20 (3H, s); 13C NMR (CDCl3, 75 MHz): δ 171.73, 159.48, 129.61, 129.47, 







Preparation of compound 4-59: To a solution of 4-58 (50 mg, 0.17 mmol) in 
dry DMF (1 mL) were added Cs2CO3 (66 mg, 0.2 mmol) and BnBr (41 µL, 0.34 
mmol) at 0 oC and the reaction mixture was stirred for 2 h at rt. After completion of the 
reaction, it was extracted with Et2O. The organic layer was washed with brine and 
dried over Na2SO4. The solvent was removed under reduced pressure to get the crude 
material which was carefully purified by column chromatography over silica gel (12% 
EtOAc/hexane) to obtain pure 4-59 (59 mg, 90%) as a colourless oil. 
Rf = 0.45 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 7.36-7.33 (5H, 
m) 7.20 (2H, d, J = 8.2 Hz), 6.86 (2H, d, J = 8.2 Hz), 5.19 (1H, d, J = 12.0 Hz), 5.15 
(1H, d, J = 12.0 Hz), 4.46-4.40 (2H, m), 4.04 (1H, s), 3.80 (3H, s), 3.46 (1H, d, J = 
10.1 Hz), 3.30 (1H, d, J = 10.1 Hz), 3.16 (1H, s) 1.22 (3H, s); 13C NMR (CDCl3, 125 
MHz): δ 169.18, 159.42, 134.92, 129.46, 128.63, 128.56, 128.43, 113.86, 74.45, 74.24, 
73.20, 67.55, 65.55, 55.27, 20.63; (ESI-MS): m/z [M+Na]+ 408.0. 
 
 
Preparation of compound 4-66R: To a solution of compound 4-65R (110 mg, 
0.25 mmol) in dry Et2O (2 mL) was added LiBH4 (44 mg, 2.0 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 2 h. After complete consumption of the 
starting material MeOH was added slowly at 0 oC until a clear solution appeared and 
then it was evaporated to get the crude material. 1M HCl was added to the viscous 
material and then extracted with EtOAc. The organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure to get the crude product 
which was purified over silica gel (6% EtOAc/hexane) to afford 4-66R (80 mg, 80%) 





Rf = 0.5 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.23 (2H, d, J = 
8.5 Hz), 6.88 (2H, d, J = 8.5 Hz), 4.49 (1H, d, J = 11.5 Hz), 4.41 (1H, d, J = 11.5 Hz), 
3.82-3.77 (4H, m), 3.48-3.44 (2H, m), 3.32 (1H, d, J = 9.3 Hz), 2.51-2.50 (1H, m), 
1.26 (3H, s), 0.94 (9H, t, J = 4.2 Hz), 0.59 (6H, q, J = 7.7 Hz). 
 
 
Preparation of compound 4-67R: To a solution of compound 4-66R (140 mg, 
0.35 mmol) in pyridine (4 mL) was added Ac2O (216 µL, 2.2 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 2 h. After complete consumption of the 
starting material, 10% citric acid was added and it was extracted with Et2O. The 
organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude product which was purified over silica gel (8% 
EtOAc/hexane) to afford 4-67R (140 mg, 90%) as a colourless oil. 
Rf = 0.65 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.25 (2H, d, J = 
9.0 Hz), 6.88 (2H, d, J = 9.0 Hz), 4.48-4.39 (3H, m), 4.17-4.10 (1H, m), 3.81 (3H, s), 
3.77 (1H, d, J = 2.4 Hz), 3.36 (1H, d, J = 9.6 Hz), 3.32 (1H, d, J = 9.6 Hz), 2.10 (3H, 
s), 1.18 (3H, s), 0.92 (9H, t, J = 7.7 Hz), 0.57 (6H, q, J = 7.2 Hz); 13C NMR (CDCl3, 
75 MHz): δ 170.82, 159.29, 129.52, 113.74, 76.23, 74.76, 72.97, 65.72, 64.15, 55.24, 
21.87, 20.81, 6.94, 6.44. 
 
Preparation of compound 4-68R: To a solution of compound 4-67R (120 mg, 
0.27 mmol) in CH2Cl2/H2O (3.6 mL/ 0.4 mL) was added DDQ (156 mg, 0.67 mmol) at 





reaction, it was directly transferred into a silica gel column and purified with 15% 
EtOAc/hexane to obtain 4-68R (65 mg, 75%) as a colourless oil. 
Rf = 0.35 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 4.52-4.48 (1H, 
dd, J = 11.5, 2.6 Hz), 4.19-4.12 (1H, dd, J = 11.3, 9.7 Hz), 3.82-3.78 (1H, dd, J = 9.7, 
2.6 Hz), 3.58 (1H, d, J = 11.3 Hz), 3.43 (1H, d, J = 11.3 Hz), 2.11 (3H, s), 1.17 (3H, s), 
0.95 (9H, t, J = 7.7 Hz), 0.62 (6H, q, J = 8.2 Hz); 13C NMR (CDCl3, 75 MHz): δ 
170.85, 76.83, 68.16, 64.82, 64.29, 20.75, 20.49, 6.90, 6.55. 
 
 
Preparation of compound 4-69R: To a solution of compound 4-68R (30 mg, 
0.1 mmol) in dry CH2Cl2 (2 mL) were added TEMPO (3 mg, 0.02 mmol) and 
diacetoxyiodobenzene (77 mg, 0.25 mmol) at 0 oC and the reaction mixture was 
allowed to stir for 12 h at rt. CH2Cl2 was concentrated and directly transferred into a 
silica gel column and purified with 3% EtOAc/hexane to obtain 4-69R (22 mg, 68%) 
as a colourless oil. 
Rf = 0.65 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 9.61 (1H, s), 
4.30-4.17 (2H, m), 3.69-3.65 (1H, m), 2.08 (3H, s), 1.37 (3H, s), 0.96 (9H, t, J = 7.7 
Hz), 0.66 (6H, q, J = 8.2 Hz); 13C NMR (CDCl3, 75 MHz): δ 202.00, 170.32, 81.16, 
65.59, 62.61, 20.66, 20.38, 6.82, 6.47. 
 
 
Preparation of compound 4-70R: To a solution of compound 4-69R (25 mg, 





butene (500 µL), NaClO2 (14 mg, 0.16 mmol) and NaH2PO4 (38 mg, 0.32 mmol) in 1 
mL H2O at 0 oC and the reaction mixture was allowed to stir for 12 h at rt. THF was 
removed under reduced pressure and 5 mL 1M HCl was added and then extracted with 
EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure to get the residue which was dissolved in 2 mL sat. NaHCO3 
solution and extracted with Et2O. The aqueous layer was acidified with 2 mL 3M HCl 
and then extracted with EtOAc. The organic layer was washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to obtain 4-70R (9 mg, 50%) as a 
colourless oil. 
Rf = 0.2 (TLC, 15% MeOH/CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ 4.28 (2H, d, J = 





Preparation of compound 4-71R: To a solution of compound 4-70R (25 mg, 
0.12 mmol) in tBuOH (1 mL) were added DMAP (2 mg) and (Boc)2O (110 mg, 0.48 
mmol) at 0 oC and the reaction mixture was allowed to stir for 14 h at rt. The reaction 
mixture was directly transferred into a silica gel column and purified with 4% 
EtOAc/hexane to obtain 4-71R (24 mg, 56%) as a colourless oil. 
Rf = 0.6 (TLC, 15% EtOAc/hexane); 1H NMR (CD3OD, 500 MHz): δ 4.46-4.43 (1H, 
dd, J = 6.8, 1.5 Hz), 4.16-4.12 (1H, dd, J = 6.8, 5.7 Hz), 4.06-4.04 (1H, dd, J = 5.7, 1.5 





MHz): δ 170.49, 168.34, 151.29, 83.18, 82.97, 81.51, 64.51, 63.41, 27.76, 27.65, 
20.68, 17.29; (ESI-MS): m/z [M+Na]+ 395.9. 
 
 
Preparation of compound 4-75R: To a solution of compound 4-71R (13 mg, 
0.03 mmol) in MeOH (1 mL) was added NaOMe (2 mg) at 0 oC and the reaction 
mixture was allowed to stir for 15 min. The reaction mixture was concentrated, 
transferred into a silica gel column and purified with 4% EtOAc/hexane to obtain 4-
75R (8 mg, 70%) as a colourless oil. 
Rf = 0.5 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 4.26-4.23 (1H, 
dd, J = 12.0, 4.0 Hz), 4.21-4.17 (1H, dd, J = 12.0, 8.5 Hz), 3.74-3.71 (1H, dd, J = 8.5, 
4.0 Hz), 1.52 (9H, s), 1.49 (9H, s), 1.46 (3H, s); 13C NMR (CDCl3, 75 MHz): δ 173.18, 
153.01, 84.18, 82.77, 75.73, 66.36, 65.43, 27.83, 27.70, 23.71. 
 
Preparation of compound 4-77R: To a solution of compound 4-76R (200 mg, 
0.67 mmol) in dry CH2Cl2 (20 mL) were added DIPEA (234 µL, 1.34 mmol), 
ethylamine hydrochloride salt (83 mg, 1.01 mmol), HATU (300 mg, 0.8 mmol) and 
HOAt (9.5 mg, 0.08 mmol) at -10 oC and the reaction mixture was allowed to stir for 
12 h at rt. The reaction was extracted with CH2Cl2. The organic layer was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure to get the crude 
product which was purified over silica gel (20% EtOAc/hexane) to afford 4-77R (175 





Rf = 0.35 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.27 (2H, d, J = 
8.6 Hz), 6.89 (2H, d, J = 8.6 Hz), 6.72 (1H, br), 4.72 (1H, s), 4.54 (2H, s), 4.29 (1H, s), 
3.80 (3H, s), 3.50-3.30 (4H, m), 1.17 (3H, t, J = 7.2 Hz), 1.06 (3H, s); 13C NMR 
(CDCl3, 75 MHz): δ 129.58, 113.78, 74.92, 74.58, 73.21, 65.42, 55.26, 34.41, 19.94, 
14.64; (ESI-MS): m/z [M+Na]+ 345.0, [M-H]- 321.0. 
 
 
Preparation of compound 4-78R: To a solution of compound 4-77R (200 mg, 
0.62 mmol) in dry CH2Cl2 (5 mL) were added Et3N (0.69 mL, 4.97 mmol) and 
TESOTf (0.70 mL, 3.10 mmol) slowly at 0 oC and the reaction mixture was allowed to 
stir over night at rt. CH2Cl2 was used for extraction and washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to get the crude product which was 
purified over silica gel (10% EtOAc/hexane) to afford 4-78R (257 mg, 95%) as a 
colourless oil.  
Rf = 0.5 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 7.24 (2H, d, J = 
9.0 Hz), 6.87 (2H, d, J = 9.0 Hz), 4.45 (1H, d, J = 11.5 Hz), 4.41 (1H, d, J = 11.5 Hz), 
4.00 (1H, s), 3.80 (3H, s), 3.44 (1H, d, J = 9.0 Hz), 3.36 (1H, d, J = 9.0 Hz), 3.30-3.21 
(2H, m), 1.33 (3H, s), 1.10 (3H, t, J = 7.5 Hz), 0.95 (9H, t, J = 7.5 Hz), 0.61 (6H, q, J = 
7.5 Hz); 13C NMR (CDCl3, 75 MHz): δ 167.59, 159.25, 129.87, 129.44, 113.71, 77.32, 







Preparation of compound 4-79R: To a solution of compound 4-78R (100 mg, 
0.23 mmol) in CH2Cl2/H2O (9 mL/1 mL) was added DDQ (110 mg, 0.46 mmol) at 0 
oC and the reaction mixture was allowed to stir for 2 h at rt. After completion of the 
reaction, it was directly transferred into a silica gel column and purified with 15% 
EtOAc/hexane to obtain 4-79R (43 mg, 60%) as a colourless oil. 
Rf = 0.35 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 6.33 (1H, br), 
4.03 (1H, s), 3.55 (1H, d, J = 11.4 Hz), 3.46 (1H, d, J = 11.4 Hz), 3.38-3.27 (2H, m), 
1.42 (3H, s), 1.17 (3H, t, J = 7.2 Hz), 0.95 (9H, t, J = 7.5 Hz), 0.61 (6H, q, J = 7.5 Hz); 
13C NMR (CDCl3, 75 MHz): δ 168.34, 77.84, 70.48, 68.92, 34.48, 23.28, 14.58, 6.90, 
6.62; (ESI-MS): m/z [M+H]+ 317.1, [M+Na]+ 339.0, [M-H]- 315.0. 
 
 
Preparation of compound 4-82: To a solution of  compound 4-81 (50 mg, 
0.27 mmol) in dry THF (2 mL) was added a 1.8 M solution of n-BuLi in cyclohexane 
(159 µL, 0.29 mmol) at -78 oC and the reaction mixture was stirred for 30 minute. 
After 30 minute, benzylpyruvate (58 mg, 0.32 mmol) in THF (1 mL) was added 
dropwise to the reaction mixture at -78 oC and the mixture was stirred for 4 h. The 
reaction mixture was quenched with sat. NH4Cl solution -78 oC and then extracted 
with Et2O. The extract was washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure to get the crude product which was purified over silica gel (4% 
EtOAc/hexane) to afford 4-82 (20 mg, 20%) as a colourless oil. 
Rf = 0.4 (TLC, 15% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.41-7.33 (5H, 





3.5 Hz), 3.70 (3H, s), 3.53 (3H, s), 3.50 (1H, s), 2.35-2.25 (1H, m), 1.55 (3H, s), 1.05 
(3H, d, J = 6.0 Hz), 0.64 (3H, d, J = 6.9 Hz); (ESI-MS): m/z [M+H]+ 363.1, [M+Na]+ 
385.1.  
 
Preparation of compound 4-86: To a solution of compound 4-82 (20 mg, 0.06 
mmol) in THF/ACN (0.5 mL/1.0 mL) was added 0.25N HCl (550 µL) at 0 oC and the 
reaction mixture was stirred for 12 h. The solvent was evaporated and the residue was 
dissolved in MeOH (0.5 mL). (Boc)2O (19 µL, 0.09 mmol) was added and the mixture 
was stirred over night. The reaction mixture was extracted with EtOAc. The organic 
layer was washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure to get the crude product which was purified over silica gel (10% 
EtOAc/hexane) to afford 4-86 (4 mg, 20% over two steps) as a colourless oil. 
Rf = 0.4 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.37 (5H, br), 
5.30 (1H, d, J = 11.0 Hz), 5.24 (2H, s), 4.81 (1H, d, J = 10.2 Hz), 3.56 (3H, s), 3.42 
(1H, s), 1.45 (12H, s); (ESI-MS): m/z [M+Na]+ 390.0.   
 
Preparation of compound 4-87: To a solution of compound 4-86 (4 mg, 0.01 
mmol) in MeOH
 
(1 mL) was added 10% Pd/C (5 mg) and the reaction mixture was 
stirred under hydrogen atmosphere (1 atm.) for 2 h. The product was eluted with 
MeOH through celite pad. The solvent was concentrated under reduced pressure to 





Rf = 0.3 (TLC, 15% MeOH/CH2Cl2); 1H NMR (CDCl3, 300 MHz): δ 5.40 (1H, br), 
4.78 (1H, br), 3.74 (3H, s), 1.46 (12H, s); (ESI-MS): m/z [M+Na]+ 300.0, [M-H]- 
275.9. 
 
Preparation of compound 4-93: To a solution of compound 4-92 (270 mg, 
1.02 mmol) in tBuOH/H2O (10 mL/10 mL) were added AD-mix α (1.4 g, 1.4 g/mmol) 
and methanesulfonamide (100 mg, 100 mg/mmol)  at -1 oC and the reaction mixture 
was allowed to stir for 96 h at that temperature. The reaction was quenched by addition 
of Na2SO3 (1.5 g, 1.48 mg/mmol) and stirred for 1 h at rt until it became colourless. 
CH2Cl2 was used for extraction and the organic layer was washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure to get the crude product which 
was purified over silica gel to afford 4-93 (260 mg, 85%) as a colourless oil. 
Rf = 0.2 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.24 (2H, d, J = 
8.6 Hz), 6.86 (2H, d, J = 8.6 Hz), 4.44 (2H, s), 4.20-4.09 (3H, m), 3.8 (3H, s), 3.47 
(1H, d, J = 9.4 Hz), 3.37 (1H, d, J = 9.4 Hz), 3.18 (1H, br), 1.27-1.23 (6H, m); 13C 
NMR (CDCl3, 75 MHz): δ 172.84, 159.23, 129.65, 129.33, 113.69, 75.17, 74.28, 
73.19, 73.14, 61.58, 55.16, 20.62, 13.99; HRMS (ESI): m/z calcd for C15H22O6Na+ 
[M+Na]+ 321.1309, found 321.1314. 
 
Preparation of compound 4-95: To a solution of compound 4-94 (1.1 g, 3.0 
mmol) in acetone/H2O (100 mL/25 mL) was added NaN3 (1.4 g, 21.6 mmol) and the 





material (checked by TLC), acetone
 
was evaporated in vacuo and the residue was 
dissolved in Et2O. 20% H2SO4 (15 mL) was added carefully at 0 oC and the reaction 
mixture was allowed to stir for 12 h at rt. Et2O was used for extraction and the organic 
layer was washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure to get the crude product which was purified over silica gel (15% 
EtOAc/hexane) to afford 4-95 (690 mg, 70%) as a colourless oil. 
Rf = 0.45 (TLC, 25% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.25-7.22 (2H, 
m), 6.89-6.86 (2H, m), 4.44 (2H, s), 4.14 (2H, q, J = 7.0 Hz), 4.02 (1H, s), 3.80 (3H, 
s), 3.47 (1H, d, J = 9.0 Hz), 3.41-3.38 (2H, m), 1.27-1.22 (6H, m); 13C NMR (CDCl3, 
75 MHz): δ 168.91, 159.33, 129.65, 129.47, 113.73, 74.32, 73.74, 73.18, 66.52, 61.88, 
55.22, 22.25, 13.98; (ESI-MS): m/z [M+Na]+ 346.0. 
 
 
Preparation of compound 4-96: To a solution of compound 4-95 (400 mg, 
1.23 mmol) in dry CH2Cl2 (10 mL) were added Et3N (686 µL, 4.95 mmol) and 
TESOTf (700 µL, 3.08 mmol) slowly at 0 oC and the reaction mixture was allowed to 
stir for 2 h. at that temperature. CH2Cl2 was added and extracted. The organic layer 
was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to 
get the crude product which was purified over silica gel to get pure 450 mg (1.03 
mmol) of protected compound and then it was dissolved in CH2Cl2 (9 mL). To this 
solution were added 850 µL phosphate buffer (pH 7.5) and DDQ (583 mg, 2.6 mmol) 
at 0 oC and the reaction mixture was allowed to stir for 3 h at rt. After completion of 





purified with 7.5% EtOAc/hexane to obtained 308 mg of alcohol. To a solution of the 
alcohol (308 mg, 0.97 mmol) in dry CH2Cl2 (24 mL) were added TEMPO (30 mg, 0.2 
mmol) and diacetoxyiodobenzene (940 mg, 2.91 mmol) at 0 oC and the reaction 
mixture was allowed to stir for 12 h at rt. CH2Cl2 was concentrated and directly 
transferred into a silica gel column and purified with 3% EtOAc/hexane to obtain 4-96 
(218 mg, 56% over three steps) as a colourless oil. 
Rf = 0.6 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 9.64 (1H, s), 4.26 
(2H, q, J = 7.0 Hz), 3.86 (1H, s), 1.41 (3H, s), 1.32 (3H, t, J = 7.2 Hz), 0.96 (9H, t, J = 
7.9 Hz), 0.64 (6H, q, J = 7.9 Hz); 13C NMR (CDCl3, 125 MHz): δ 200.39, 167.25, 
81.74, 67.20, 62.14, 20.16, 14.05, 6.71, 6.35. 
 
Preparation of compound 4-97: To a solution of compound 4-96 (36 mg, 0.12 
mmol) in THF/H2O/tBuOH (1.6 mL/1.6 mL/0.4 mL) were added 2-methyl-2-butene 
(800 µL), NaClO2 (21 mg, 0.23 mmol) and NaH2PO4 (55 mg, 0.46 mmol) in 1 mL H2O 
at 0 oC and the reaction mixture was allowed to stir for 12 h at rt. THF was removed 
under reduced pressure and 5 mL 1M HCl was added and then extracted with EtOAc. 
The organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to obtain the residue which was dissolved in 2 mL sat. NaHCO3 
solution and extracted with Et2O. The aqueous layer was acidified with 2 mL 3M HCl 
and extracted with EtOAc. The organic layer was washed with brine, dried over 






Rf = 0.2 (TLC, 15% MeOH/CH2Cl2); 1H NMR (CD3OD, 300 MHz): δ 4.30-4.26 (2H, 
m), 4.08 (1H, s), 1.47 (3H, s), 1.33 (3H, t, J = 6.9 Hz); 13C NMR (CD3OD, 75 MHz): δ 
177.33, 169.63, 78.35, 67.96, 62.88, 23.79, 14.46.  
 
Preparation of compound 4-99: To a solution of compound 4-97 (15 mg, 0.07 
mmol) in MeOH
 
(2 mL) was added 10% Pd/C (9 mg) and the reaction mixture was 
stirred under hydrogen atmosphere (1 atm.) for 2 h. The amine was eluted with MeOH 
through celite pad. The solvent was concentrated under reduced pressure to get the 
crude product which was dissolved in 6M HCl (5 mL) and refluxed for 24 h to afford 
4-99 (11 mg, 85% over two steps) as a viscous material.  




Preparation of compound 4-101: To a solution of compound 4-100 (0.5 mL, 
8.9 mmol) in THF
 
(22 mL) was added NaH (385 mg, 16.0 mmol) at 0 oC and the 
reaction mixture was stirred for 15 minute. Next, p-methoxybenzyl chloride (1.8 mL, 
13.4 mmol) and TBAI (430 mg, 1.15 mmol) were added to the reaction mixture at 0 oC 
and it was stirred for 16 h at rt. The reaction was quenched carefully with dropwise 
addition of sat. NH4Cl solution and then extracted with Et2O. The organic layer was 
washed with brine and dried over Na2SO4. The solvent was concentrated under 
reduced pressure to get the crude product which was purified over silica gel (5% 





Rf = 0.5 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.29 (2H, d, J = 
8.7 Hz), 6.90 (2H, d, J = 8.7 Hz), 4.55 (2H, s), 4.14 (2H, d, J = 2.4 Hz), 3.81 (3H, s), 
2.47 (1H, t, J = 2.4 Hz); 13C NMR (CDCl3, 75 MHz): δ 159.36, 129.70, 129.27, 
113.78, 79.73, 74.43, 71.06, 56.60, 55.17. 
 
Preparation of compound 4-103: To a solution of compound 4-101 (330 mg, 
1.88 mmol) in dry THF (6 mL) was added a n-BuLi (1.0 mL, 2.0 M solution in 
cyclohexane, 2.0 mmol) at -78 oC and the reaction mixture was stirred for 30 minute. 
After 30 minute, methyl cyanoformate (240 µL, 2.82 mmol) was added dropwise to the 
reaction mixture at -78 oC and it was stirred for 1 h at that temperature. It was then 
warmed to -40 oC and stirred for 15 minute. The reaction mixture was quenched with 
sat. NH4Cl solution at -40 oC and then extracted with Et2O. The extract was washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure to get the 
crude product which was purified over silica gel (7% EtOAc/hexane) to afford 4-103 
(420 mg, 96%) as a colourless oil. 
Rf = 0.35 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 500 MHz): δ 7.29 (2H, d, J = 
8.9 Hz), 6.90 (2H, d, J = 8.9 Hz), 4.56 (2H, s), 4.27 (2H, s), 3.82 (3H, s), 3.81 (3H, s); 
13C NMR (CDCl3, 125 MHz): δ 159.62, 153.58, 129.88, 128.76, 113.95, 83.80, 77.88, 
71.68, 56.33, 55.27, 52.78. 
 
Preparation of compound 4-104: To the suspension of CuI (640 mg, 3.36 





reaction mixture was allowed to stir for 30 minute at that temperature. To this 
colourless solution was added 4-103 (555 mg, 2.24 mmol) drop wise at -78 oC and 
stirred at that temperature for 4 h. To this reaction mixture was added 16 mL sat. 
NH4Cl solution drop wise and after complete addition it was kept at -78 oC for 10 
minute. The reaction mixture was then warmed up slowly to rt. The precipitate was 
filtered and the filtrate was extracted with Et2O. The organic layer was washed with 
brine and dried over Na2SO4. The solvent was removed under reduced pressure to get 
the crude product which was purified over silica gel (1.5% EtOAc/hexane) to obtain 4-
104 (400 mg, 69%, exclusive Z-isomer) as a colourless oil. 
Rf = 0.7 (TLC, 5% EtOAc/hexane); IR (thin film): vmax = 2952, 2838, 1716, 1613, 
1515, 1444, 1363, 1248, 1153, 1035, 1032, 820 cm-1; 1H NMR (CDCl3, 500 MHz): δ 
7.25 (2H, d, J = 8.2 Hz), 6.86 (2H, d, J = 8.2 Hz), 5.74 (1H, s), 4.61 (2H, s), 4.43 (2H, 
s), 3.78 (3H, s), 3.66 (3H, s), 1.98 (3H, s); 13C NMR (CDCl3, 125 MHz): δ 166.29, 
159.18, 157.47, 130.32, 129.23, 116.70, 113.74, 72.35, 68.99, 55.20, 50.97, 21.69; 
HRMS (ESI): m/z calcd for C14H18O4Na+ [M+Na]+ 273.1097, found 273.1106.  
 
 
Preparation of compound 4-105: To a solution of compound 4-104 (80 mg, 
0.30 mmol) in tBuOH/H2O (1:1, 8 mL) were added AD-mix α (420 mg, 1.4 g/mmol) 
and methanesulfonamide (30 mg, 100 mg/mmol)  at -1 oC and the reaction mixture 
was allowed to stir for 96 h at that temperature. The reaction was quenched by addition 
of Na2SO3 (444 mg, 1.48 mg/mmol) and stirred for 1 h at rt until it became colourless. 
CH2Cl2 was used for extraction and the organic layer was washed with brine, dried 





was purified over silica gel (20% EtOAc/hexane) to obtain 4-105 (75 mg, 85%) as a 
colourless oil. The enantiomeric excess was determined through HPLC analysis with 
Chiralpak-IA column (0.46 cm ϕx25 cm) using hexanes/2-propanol (90:10) at a flow 
rate of 1.0 mL/min; detection UV 210 nm; 82 % ee.  
Rf = 0.3 (TLC, 25% EtOAc/hexane); [α]D25 = -16.2 (c = 4.0, CHCl3); IR (thin film): 
vmax = 3473, 2954, 2863, 1728, 1613, 1515, 1248, 1174, 1091, 1032 cm-1; 1H NMR 
(CDCl3, 500 MHz): δ 7.23 (2H, d, J = 8.9 Hz), 6.88 (2H, d, J = 8.9 Hz), 4.43 (2H, s), 
4.10 (1H, s), 3.80 (3H, s), 3.70 (3H, s), 3.47 (1H, d, J = 9.5 Hz), 3.37 (1H, d, J = 8.9 
Hz), 1.22 (3H, s); 13C NMR (CDCl3, 125 MHz): δ 173.39, 159.35, 129.44, 113.80, 
75.26, 74.31, 73.32, 73.18, 55.25, 52.39, 20.65; HRMS (ESI): m/z calcd for 





















Preparation of compound 4-106: To a solution of compound 4-105 (835 mg, 
2.94 mmol) in CH2Cl2 (20 mL) were added Et3N (1.03 mL, 7.35 mmol) and SOCl2 
(540 µL, 7.35 mmol) carefully at 0 oC and the reaction mixture was allowed to stir for 
30 minute at that temperature. After consumption of the starting material (checked by 
TLC), CH2Cl2 was evaporated in vacuo and the resulting cyclic sulphite was eluted 
with Et2O through silica plug. The organic layer was washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to get the crude product which was 
dissolved in CH3CN (14 mL). To this solution were added RuCl3 (2 mg), NaIO4 (1.13 
g, 5.3 mmol), and H2O (18 mL) at 0 oC and the reaction mixture was allowed to stir for 









extracted. The organic layer was washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure to get the crude product which was purified over 
silica gel (20% EtOAc/hexane) to afford 4-106 (800 mg, 79%) as a colourless oil.   
Rf = 0.45 (TLC, 20% EtOAc/hexane); [α]D25 = +34.3 (c = 4.2, CHCl3); IR (thin film): 
vmax = 2957, 2875, 1766, 1742, 1612, 1516, 1440, 1418, 1302, 1249, 1215, 1176 cm-1; 
1H NMR (CDCl3, 300 MHz): δ 7.21 (2H, d, J = 8.7 Hz), 6.88 (2H, d, J = 8.7 Hz), 4.99 
(1H, s), 4.46 (1H, d, J = 11.5 Hz ), 4.39 (1H, d, J = 11.5 Hz), 3.80 (3H, s), 3.77 (1H, d, 
J = 10.4 Hz), 3.70 (3H, s), 3.59 (1H, d, J = 10.4 Hz), 1.75 (3H, s); 13C NMR (CDCl3, 
75 MHz): δ 163.65, 159.50, 129.38, 128.72, 113.85, 91.87, 81.56, 73.35, 69.89, 55.26, 
53.02, 29.68, 22.15; HRMS (ESI): m/z calcd for C14H18O8SNa+ [M+Na]+ 369.0615, 
found 369.0624. 
 
Preparation of compound 4-107: To a solution of compound 4-106 (800 mg, 
2.31 mmol) in acetone/H2O (56 mL/14 mL) was added NaN3 (900 mg, 13.87 mmol) 
and the reaction mixture was heated at 50 oC for 9 h. After consumption of the starting 
material (checked by TLC), acetone
 
was evaporated in vacuo and the residue was 
dissolved in Et2O. 20% H2SO4 (10 mL) was added carefully at 0 oC and the reaction 
mixture was allowed to stir for 12 h at rt. Et2O was used for extraction and the organic 
layer was washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure to get the crude product which was purified over silica gel (15% 
EtOAc/hexane) to afford 4-107 (560 mg, 78%) as a colourless oil.   
Rf = 0.48 (TLC, 20% EtOAc/hexane); [α]D25 = -34.4 (c = 4.5, CHCl3); IR (thin film): 
vmax = 3512, 2909, 2864, 2114, 1733, 1613, 1514, 1248, 1207, 1175, 1094, 1032, 821 





4.43 (2H, s), 4.02 (1H, s), 3.80 (3H, s), 3.66 (3H, s), 3.47 (1H, d, J = 9.4 Hz), 3.40 
(1H, s), 3.36 (1H, d, J = 9.4 Hz), 1.26 (3H, s); 13C NMR (CDCl3, 75 MHz): δ 169.43, 
159.39, 129.62, 129.58, 113.77, 74.39, 73.70, 73.29, 66.71, 55.27, 52.52, 22.29; 
HRMS (ESI): m/z calcd for C14H19O5N3Na+ [M+Na]+ 332.1217, found 332.1229. 
 
 
Preparation of compound 4-108: To a solution of compound 4-107 (560 mg, 
1.81 mmol) in CH2Cl2 (20 mL) were added Et3N (1.02 mL, 7.25 mmol) and TESOTf 
(1.02 mL, 4.53 mmol) slowly at 0 oC and the reaction mixture was allowed to stir for 
45 minute at that temperature. CH2Cl2 was used for extraction and was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure to get the crude 
product which was purified over silica gel to get pure 680 mg (1.61 mmol) of protected 
compound. To a solution of the TES protected compound in CH2Cl2 (30 mL) were 
added 6.1 mL phosphate buffer (pH 7.5) and DDQ (912 mg, 4.02 mmol) at 0 oC and 
the reaction mixture was allowed to stir for 3 h at rt. After completion of the reaction, 
the reaction mixture was directly transferred into a silica gel column and purified with 
7.5% EtOAc/hexane to obtain 4-108 (268 mg, 70% over two steps) as a colourless oil. 
Rf = 0.5 (TLC, 20% EtOAc/hexane); [α]D25 = +15.6 (c = 1.0, CHCl3); IR (thin film): 
vmax = 3440, 2956, 2878, 2114, 1747, 1458, 1436, 1277, 1243, 1174, 1057, 1010, 746 
cm-1; 1H NMR (CDCl3, 500 MHz): δ 3.94 (1H, s), 3.79 (3H, s), 3.65-3.57 (1H, dd, J = 
11.4, 7.6 Hz), 3.56-3.53 (1H, dd, J = 11.4, 7.6 Hz), 2.00-1.98 (1H, m), 1.38 (3H, s), 
0.97 (9H, t, J = 8.2 Hz), 0.64 (6H, q, J = 8.2 Hz); 13C NMR (CDCl3, 125 MHz): δ 
169.20, 78.31, 68.40, 67.38, 52.40, 21.93, 6.83, 6.58; HRMS (ESI): m/z calcd for 







Preparation of compound 4-109: To a solution of compound 4-108 (240 mg, 
0.8 mmol) in dry CH2Cl2 (25 mL) were added TEMPO (25 mg, 0.16 mmol) and 
diacetoxyiodobenzene (773 mg, 2.4 mmol) at 0 oC and the reaction mixture was 
allowed to stir for 10 h at rt. CH2Cl2 was concentrated and directly transferred into a 
silica gel column and purified with 3% EtOAc/hexane to obtain 168 mg (70%) of 
aldehyde which was again dissolved in THF/H2O/tBuOH (12 mL/12 mL/2.4 mL) and 
to this solution were added 4.8 mL 2-methyl-2-butene, NaClO2(160 mg, 1.8 mmol) 
and NaH2PO4 (400 mg, 3.34 mmol) in 6 mL H2O at 0 oC and the reaction mixture was 
allowed to stir for 12 h at rt. THF was removed under reduced pressure and 50 mL 1M 
HCl was added and then extracted with EtOAc. The organic layer was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure to get the residue 
which was dissolved in 12 mL sat. NaHCO3 solution and extracted with Et2O. The 
aqueous layer was acidified with 10 mL 3M HCl and then extracted with EtOAc. The 
organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to obtain 4-109 (101 mg, 63% over two steps) as a colourless oil. 
Rf = 0.2 (TLC, 5% CH3OH/CH2Cl2); [α]D25 = -44.1 (c = 2.0, CHCl3); IR (thin film): 
vmax = 3490, 2959, 2117, 1730, 1438, 1263, 1215, 1182, 1106, 1013, 847 cm-1; 1H 
NMR (CDCl3, 300 MHz): δ 4.16 (1H, s), 3.88 (3H, s), 1.57 (3H, s); 13C NMR (CDCl3, 
75 MHz): δ 176.61, 167.99, 66.37, 53.03, 23.05; HRMS (ESI): m/z calcd for 











Preparation of compound 5-3: To a solution of heptanoic acid (1.0 g, 7.7 
mmol) in THF (30 mL) were added Et3N (3.2 mL, 23.1 mmol) and pivaloyl chloride 
(1.2 mL, 8.5 mmol) at -20 oC and the reaction mixture was stirred for 1 h. Lithium 
chloride (500 mg, 11.8 mmol) and (S)-4-benzyl-2-oxazolidinone (1.3 g, 7.4 mmol) 
were added to the reaction mixture and it was allowed to stir for 14 h at rt. The 
reaction was quenched by addition of 0.2M HCl (10 mL), and THF was removed in 
vacuo. The residue was extracted with EtOAc. The organic layer was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure to get the crude 
product which was purified over silica gel (5% EtOAc/hexane) to afford 5-3 (1.78 g, 
80%) as a colourless oil.  
Rf = 0.45 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.40-7.24 (5H, 
m), 4.75-4.68 (1H, m), 4.27-4.18 (2H, m), 3.33 (1H, dd, J = 13.2, 3.0 Hz), 3.07-2.77 
(3H, m), 1.78-1.69 (2H, m), 1.45-1.36 (6H, m), 0.96 (3H, t, J = 7.2 Hz); 13C NMR 
(CDCl3, 75 MHz): δ 173.43, 153.44, 135.33, 129.40, 128.93, 127.31, 66.13, 55.13, 
37.93, 35.52, 31.54, 28.78, 24.22, 22.49, 14.00; (ESI-MS): m/z [M+Na]+ 312.1. 
 
 
Preparation of compound 5-4: To a stirred solution of N,N-diisopropylamine 
(0.76 mL, 5.40 mmol) in dry THF (5 mL) was added n-BuLi (4.2 mL, 1.3M solution in 





freshly prepared LDA was added to a solution of compound 5-3 (1.04 g, 3.6 mmol) in 
dry THF (10 mL) dropwise at -78 oC and then the mixture was allowed to stir for 1 h. 
After 1 h, MeI (1.4 mL, 21.6 mmol) was added dropwise at -78 oC to the reaction 
mixture and it was stirred for 16 h. The reaction mixture was quenched with sat. 
NH4Cl solution and extracted with Et2O. The extract was washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure to get the crude product which 
was purified over silica gel (5% EtOAc/hexane) to afford 5-4 (716 mg, 66%) as a 
colourless oil. 
Rf = 0.35 (TLC, 10% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 7.28-7.20 (5H, 
m), 4.71-4.65 (1H, m), 4.23-4.15 (2H, m), 3.74-3.67 (1H, m), 3.26 (1H, dd, J = 13.2, 
3.0 Hz), 2.80-2.72 (1H, m), 1.78-1.71 (1H, m), 1.42-1.21 (10H, m), 0.88 (3H, t, J = 7.2 
Hz); 13C NMR (CDCl3, 75 MHz): δ 177.36, 153.06, 135.35, 129.44, 128.92, 127.32, 
65.99, 55.35, 37.92, 37.70, 33.37, 31.81, 29.57, 26.91, 22.51, 17.34, 14.00. 
 
 
Preparation of compound 5-5: To a solution of compound 5-4 (716 mg, 2.36 
mmol) in dry Et2O (10 mL) was added LiBH4 (155 mg, 7.08 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 30 minute at rt. MeOH was added slowly to 
quench and after getting the clear solution, the solvent was evaporated and the residue 
was extracted with CH2Cl2. The organic layer was washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to get the crude product which was 






Rf = 0.35 (TLC, 20% EtOAc/hexane); 1H NMR (CDCl3, 300 MHz): δ 3.51-3.45 (1H, 
m), 3.41-3.35 (1H, m), 1.76 (1H, s), 1.61-1.55 (1H, m), 1.39-1.23 (7H, m), 1.11-1.05 
(1H, m), 0.90-0.84 (6H, m); 13C NMR (CDCl3, 75 MHz): δ 68.39, 35.74, 33.09, 32.12, 
26.62, 22.62, 16.55, 14.05. 
 
Preparation of compound 5-14: To a solution of compound 5-5 (1.0 g, 7.7 
mmol) in dry THF (80 mL) were added PPh3 (2.83 g, 10.77 mmol), 1-phenyl-1H-
tetrazole-5-thiol (1.9 g, 10.77 mmol) and DIAD (2.16 mL, 10.77 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 8 h at rt. THF was concentrated and directly 
transferred into a silica gel column and purified with 5% EtOAc/hexane to obtain 5-14 
(1.6 g, 76%) as a colourless oil. 
Rf = 0.6 (TLC, 15% EtOAc/hexane); [α]D25 = +1.4 (c = 1.84, CHCl3); IR (thin film): 
vmax = 2957, 2927, 2856, 1600, 1500, 1386, 1240, 760 cm-1; 1H NMR (CDCl3, 500 
MHz): δ 7.54-7.51 (4H, m), 5.24-5.21 (1H, m), 3.47-3.43 (1H, dd, J = 12.6, 5.7 Hz), 
3.27-3.23 (1H, m), 1.93-1.90 (1H, m), 1.49-1.34 (2H, m), 1.31-1.22 (7H, m), 1.03-1.01 
(3H, d, J = 6.3 Hz), 0.87 (3H, t, J = 6.95 Hz ); 13C NMR (CDCl3, 125 MHz): δ 154.72, 
133.77, 130.00, 129.71, 123.85, 74.29, 40.53, 35.84, 32.91, 31.86, 26.42, 22.52, 21.54, 
19.05, 13.98; HRMS (ESI): m/z calcd for C15H22N4SNa+ [M+Na]+ 313.1457, found 
313.1455.   
 
 
Preparation of compound 5-15: To a solution of compound 5-14 (1.02 g, 3.52 
mmol) in absolute EtOH
 





dissolved in 19 mL H2O2 at 0 oC and the reaction mixture was allowed to stir for 8 h at 
rt. The solvent was evaporated and then the residue was extracted with EtOAc. The 
organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude product which was purified over silica gel (7.5% 
EtOAc/hexane) to obtain 5-15 (1.1 g, 98%) as a colourless oil..  
Rf = 0.38 (TLC, 15% EtOAc/hexane); [α]D25 = -8.3 (c = 1.75, CHCl3); IR (thin film): 
vmax = 2957, 2930, 2859, 1497, 1339, 1153, 762 cm-1; 1H NMR (CDCl3, 300 MHz): δ 
7.70-7.66 (2H, m), 7.62-7.56 (3H, m), 3.84-3.77 (1H, dd, J = 14.5, 4.9 Hz), 3.61-3.54 
(1H, dd, J = 14.5, 8.07 Hz), 2.36-2.30 (1H, m), 1.57-1.50 (1H, m), 1.38-1.28 (7H, m), 
1.15 (3H, d, J = 6.8 Hz), 0.87 (3H, t, J = 7.0 Hz ); 13C NMR (CDCl3, 75 MHz): δ 
154.08, 133.07, 131.40, 129.63, 125.13, 61.84, 36.49, 31.57, 28.22, 25.93, 22.46, 






Preparation of compound 5-18: To a solution of compound 5-15 (200 mg, 
0.62 mmol) in dry DME
 
(4 mL) was added KHMDS (1.4 mL, 0.5M in toluene, 0.7 
mmol) drop wise at -60 oC and the reaction mixture was stirred at that temperature for 
1 h. 3-(tert-butyldiphenylsilyloxy)propanal (290 mg, 0.92 mmol) in DME (4 mL) was 
added slowly at -60 oC and the reaction mixture was allowed to stir for 12 h. To this 
reaction mixture 2 mL H2O was added and it was vigorously stirred for 1 h. The 
reaction mixture was extracted with Et2O. The organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure to get the crude product 
which was purified over silica gel (1.5% EtOAc/hexane) to obtain 5-18 (89 mg, 35%) 





Rf = 0.8 (TLC, 5% EtOAc/hexane); [α]D25 = +13.5 (c = 0.6, CHCl3); IR (thin film): vmax 
= 2957, 2929, 2857, 1738, 1472, 1429, 1112, 969, 823, 736 cm-1; 1H NMR (CDCl3, 
300 MHz): δ 7.68 (4H, d, J = 5.8 Hz), 7.42-7.35 (6H, m), 5.37-5.34 (2H, m), 3.68 (2H, 
t, J = 6.6 Hz), 2.29-2.23 (2H, m), 2.05 (1H, m), 1.44-1.25 (10H, m), 1.05 (9H, s), 0.97 
(3H, d, J = 8.0 Hz), 0.87 (3H, t, J = 7.0 Hz); 13C NMR (CDCl3, 75 MHz): δ 138.66, 
135.60, 134.13, 129.48, 127.55, 124.51, 64.12, 37.07, 36.73, 36.08, 32.02, 26.96, 




Preparation of compound 5-20: To a solution of compound 5-18 (89 mg, 0.22 
mmol) in dry THF
 
(2 mL) was added TBAF (335 µL, 0.33 mmol) at 0 oC and the 
reaction mixture was allowed to stir for 2 h at rt. The reaction was quenched with sat. 
NH4Cl solution and THF was evaporated and the residue was extracted with Et2O. The 
organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude product which was purified over silica gel (10% 
EtOAc/hexane) to get 26 mg (70%) of the corresponding alcohol. To a solution of 
CrO3 (100 mg, 1.0 mmol) in 1 mL 3M H2SO4 was added the resulting alcohol 
(obtained from first step) in 2 mL acetone at 0 oC and the reaction mixture was allowed 
to stir for 3 h at rt. The reaction mixture was quenched with EtOH and filtered through 
filter paper. The filtrate was concentrated and the residue was extracted with EtOAc. 
The organic layer was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure to get the crude product which was purified over silica gel (25% 
EtOAc/hexane) to afford 5-20 (20 mg, 72%) as colourless oil. 
 Rf = 0.3 (TLC, 50% EtOAc/hexane); [α]D25 = +14.0 (c = 2.0, CHCl3); IR (thin film): 





(CDCl3, 500 MHz): δ 5.48-5.46 (2H, m), 3.07 (2H, d, J = 5.0 Hz), 1.29 (8H, br), 0.96 
(3H, d, J = 8.0 Hz), 0.86 (3H, t, J = 7.0 Hz); 13C NMR (CDCl3, 75 MHz): δ 176.66, 
141.34, 118.95, 37.55, 36.77, 36.61, 31.93, 26.86, 22.61, 20.32, 14.05; HRMS (ESI): 





Preparation of compound 6-1: To a solution of compound 3-35 (110 mg, 0.41 
mmol) in THF/H2O/MeOH (2 mL/2 mL/0.4 mL) was added LiOH (11 mg, 0.45 mmol) 
at 0 oC and the reaction mixture was allowed to stir for 2 h at that temperature. After 
completion of the reaction (checked by TLC), the reaction mixture was extracted with 
Et2O. The aqueous layer was acidified with 10% NaHSO4 to pH 2-3 and then extracted 
with EtOAc. The organic layer was washed with brine and dried over Na2SO4. The 
solvent was removed under reduced pressure to afford 6-1 (102 mg, 85%) as colourless 
oil. 
Rf = 0.2 (TLC, 5% CH3OH/CH2Cl2); [α]D25 = +17.8 (c = 0.64, CHCl3); IR (thin film): 
vmax = 3324, 2977, 2363, 1734, 1507, 1163 cm-1; 1H NMR (CDCl3, 500 MHz): δ 4.98 
(1H, br), 4.81 (2H, d, J = 35.0 Hz), 4.45 (1H, s), 2.65 (1H, br), 1.78 (3H, s), 1.42 (9H, 
s), 1.06 (3H, d, J = 6.95 Hz); 13C NMR (CDCl3, 125 MHz): δ 176.91, 155.67, 145.31, 
112.52, 80.07, 55.99, 42.94, 28.24, 20.57, 13.99; HRMS (ESI): m/z calcd for 







Preparation of compound 6-3: To a solution of compound 6-1 (60 mg, 0.25 
mmol) in dry CH2Cl2 (2 mL) were added DIPEA (87 µL, 0.5 mmol), dimethylasparate 
hydrochloride salt (73 mg, 0.37 mmol), HATU (113 mg, 0.3 mmol) and HOAt (3.5 
mg, 0.03 mmol) at -10 oC and the reaction mixture was allowed to stir for 12 h at rt. 
The reaction was extracted with CH2Cl2. The organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure to get the crude product 
which was purified over silica gel (35% EtOAc/hexane) to afford 6-3 (77 mg, 82%) as 
a colourless oil. 
Rf = 0.3 (TLC, 40% EtOAc/hexane); [α]D25 = +22.4 (c = 0.8, CHCl3); IR (thin film): 
vmax = 3317, 3256, 3077, 2979, 1747, 1682, 1655, 1652, 1557, 1519, 1434, 1367, 1303, 
1168, 1013 cm-1; 1H NMR (CDCl3, 500 MHz): δ 6.98 (1H, br), 4.87 (2H, s), 4.77 (2H, 
s), 4.20 (1H, br), 3.74 (3H, s), 3.67 (3H, s), 3.00 (1H, dd, J = 17.6, 4.4 Hz), 2.86 (1H, 
dd, J = 17.6, 4.4 Hz), 2.68 (1H, t, J = 6.9), 1.77 (3H, s), 1.42 (9H, s), 0.99 (3H, d, J = 
6.9); 13C NMR (CDCl3, 125 MHz): δ 171.21, 170.72, 155.63, 145.96, 112.34, 80.13, 
57.04, 52.66, 51.91, 48.68, 42.39, 35.98, 28.19, 21.08, 13.84; HRMS (ESI): m/z calcd 
for C18H30O7N2Na+ [M+Na]+ 409.1945, found 409.1953. 
  
 
Preparation of compound 6-15: To a solution of compound 6-3 (30 mg, 0.08 
mmol)  in dry CH2Cl2 (1 mL) was added TFA (500 µL) at 0 oC and the reaction 
mixture was allowed to stir for 2 h at rt. CH2Cl2 was concentrated under reduced 
pressure to get the dry TFA salt which was dissolved in dry CH2Cl2 (1 mL). To this 





in CH2Cl2 (1 mL), HATU (60 mg, 0.16 mmol) and HOAt (5 mg, 0.04 mmol) at -10 oC 
and the reaction mixture was allowed to stir for 12 h at rt. The reaction mixture was 
extracted with CH2Cl2. The organic layer was washed with brine, dried over Na2SO4 
and concentrated under reduced pressure to get the crude product which was purified 
over silica gel (65% EtOAc/hexane) to afford 6-15 (18 mg, 50% over two steps) as a 
white solid. 
Rf = 0.3 (TLC, 50% EtOAc/hexane); [α]D25 = -34.7 (c = 1.0, CHCl3); IR (thin film): 
vmax = 3305, 2106, 1744, 1738, 1652, 1544, 1438, 1299, 1133, 1002, 912, 856, 732 cm-
1; H NMR (CDCl3, 500 MHz): δ 7.19 (1H, d, J = 8.8 Hz), 6.99 (1H, d, J = 7.6 Hz), 
4.91 (1H, s), 4.84 (1H, s), 4.80-4.78 (1H, m), 4.57-4.54 (1H, m), 4.23 (1H, s), 3.90 
(1H, s), 3.85 (3H, s), 3.75 (3H, s), 3.69 (3H, s), 2.98 (1H, dd, J = 17.3, 4.4 Hz), 2.88 
(1H, dd, J = 17.3, 4.4 Hz), 2.80-2.77 (1H, m), 1.8 (3H, s), 1.48 (3H, s), 1.08 (3H, d, J = 
6.9 Hz); 13C NMR (CDCl3, 125 MHz): δ 172.62, 171.24, 170.67, 170.46, 169.28, 
145.60, 112.59, 65.84, 55.53, 52.90, 52.76, 52.03, 48.71, 42.14, 38.58, 35.85, 29.66, 





Preparation of compound 6-16: To a solution of compound 6-15 (20 mg, 0.04 
mmol) in THF/H2O (3 mL/150 µL) was added Me3P (300 µL, 1.0M in THF) at 0 oC 
and the reaction mixture was allowed to stir for 1 h. After complete consumption of the 
starting material, THF was removed in vacuo and extracted with EtOAc. The organic 





pressure to get the crude product which was purified over silica gel (5% 
MeOH/CH2Cl2) to afford 13 mg (0.03 mmol) of corresponding amine which was 
dissolved in dry CH2Cl2 (3 mL). To this solution were added DIPEA (15 µL, 0.09 
mmol), compound 5-20 (8 mg, 0.04 mmol) in CH2Cl2 (2 mL), HATU (35 mg, 0.09 
mmol) and HOAt (2 mg, 0.02 mmol) at -10 oC and the reaction mixture was allowed to 
stir for 12 h at rt. The reaction was extracted with CH2Cl2. The organic layer was 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure to get 
the crude product which was purified over silica gel (50% EtOAc/hexane) to obtain 6-
16 (10 mg, 40% over two steps) as a colourless oil. 
Rf = 0.38 (TLC, 40% EtOAc/hexane); [α]D25 = +18.8 (c = 0. 25, CHCl3); IR (thin film): 
vmax = 3289, 2957, 2921, 2850, 1748, 1729, 1654, 1647, 1527, 1287, 1210, 1107 cm-1; 
1H NMR (CDCl3, 500 MHz): δ 7.13 (1H, d, J = 8.8 Hz), 7.08 (1H, d, J = 8.2 Hz), 6.88 
(1H, d, J = 8.2 Hz), 5.55 (2H, m), 4.9 (1H, s), 4.84 (3H, m), 4.77 (1H, m), 4.43 (1H, 
m), 3.75 (3H, s), 3.72 (3H, s), 3.68 (3H, s), 3.0 (3H, m), 2.86 (1H, dd, J = 17.3, 4.4 
Hz), 2.75 (1H, t, J = 7 Hz), 2.16-2.13 (1H, m), 1.76 (3H, s), 1.46 (3H, s), 1.29 (8H, br), 
1.04 (3H, d, J = 6.95 Hz), 0.97 (3H, d, J = 7.0 Hz), 0.87 (3H, t, J = 7.0 Hz); 13C NMR 
(CDCl3, 125 MHz): δ 175.86, 172.74, 171.75, 171.29, 170.65, 170.03, 145.59, 142.48, 
119.93, 112.68, 76.44, 57.56, 55.19, 52.92, 52.80, 52.04, 48.66, 42.16, 40.19, 36.77, 
36.73, 35.88, 31.97, 29.69, 26.92, 23.97, 22.60, 20.93, 20.40, 14.15, 14.08; HRMS 







Preparation of compound 6-18: To a solution of 6-16 (3 mg, 0.005 mmol) in 
ClCH2CH2Cl (2 mL) was added Me3SnOH (27 mg, 0.15 mmol) and the reaction 
mixture was heated at 80 oC for 48 h. ESI mass was checked for the crude reaction 
mixture and found diacid as major product. The solvent was evaporated and the 
residue was extracted with EtOAc. The organic layer was washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure to get the crude product which 
was dissolved in THF/H2O/MeOH (1 mL/1 mL/0.2 mL). To this solution was added 
LiOH (10 mg, 0.42 mmol) at 0 oC and the reaction mixture was allowed to stir for 12 h 
at rt. The reaction was acidified with 3M HCl and extracted with EtOAc The organic 
layer was washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure to get the crude product which was purified by prep. HPLC (30-100% 
ACN/H2O) to afford 6-18 (1.3 mg, 46%) as colourless oil. 
Rf = 0.1 (TLC, 20% CH3OH/CH2Cl2); [α]D25 = -20.0 (c = 0.1, CH3OH); IR (thin film): 
vmax = 2927, 2855, 1733, 1656, 1521, 1195 cm-1; 1H NMR (CD3OD, 500 MHz): δ 
5.52-5.50 (2H, m), 4.61-4.60 (2H, m), 4.43 (1H, d, J = 6.9 Hz), 2.97 (2H, d, J = 6.9 
Hz), 2.81 (2H, t, J = 7.0 Hz), 2.67-2.65 (2H, m), 2.13 (1H, m), 1.76 (3H, s), 1.44 (3H, 
s), 1.29 (8H, br), 1.07 (3H, d, J = 6.9 Hz), 0.97 (3H, d, J = 6.9 Hz), 0.89 (3H, t, J = 7.0 
Hz); 13C NMR (CD3OD, 125 MHz): δ 176.35, 174.13, 173.95, 173.59, 173.28, 172.66, 
147.01, 142.79, 121.74, 113.38, 76.51, 57.12, 50.33, 44.33, 40.63, 38.09, 38.00, 36.83, 
33.15, 28.10, 24.45, 23.67, 20.95, 20.45, 15.55, 14.43; HRMS (ESI): m/z calcd for 



























































































































































































































































































































Table 1.  Crystal data and structure refinement for 3-15a. 
Identification code  7468 
Empirical formula  C15 H25 N O6 
Formula weight  315.36 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 6.4285(4) Å α= 79.7320(10)°. 
 b = 10.4987(6) Å β= 77.9400(10)°. 
 c = 13.6098(8) Å γ = 74.7870(10)°. 
Volume 859.34(9) Å3 
Z 2 
Density (calculated) 1.219 Mg/m3 
Absorption coefficient 0.094 mm-1 
F(000) 340 
Crystal size 0.60 x 0.60 x 0.50 mm3 
Theta range for data collection 2.03 to 27.47°. 
Index ranges -8<=h<=8, -13<=k<=13, -17<=l<=17 
Reflections collected 11336 
Independent reflections 3928 [R(int) = 0.0232] 
Completeness to theta = 27.47° 99.7 %  
Absorption correction Sadabs,(Sheldrick 2001) 
Max. and min. transmission 0.9546 and 0.9459 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3928 / 0 / 206 
Goodness-of-fit on F2 1.079 
Final R indices [I>2sigma(I)] R1 = 0.0573, wR2 = 0.1674 
R indices (all data) R1 = 0.0675, wR2 = 0.1761 
Largest diff. peak and hole 0.483 and -0.342 e.Å-3 
164 
 
 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 7468.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) -1326(2) 3934(1) 2664(1) 48(1) 
O(1) -1061(2) 5634(1) 3506(1) 63(1) 
O(2) 2055(2) 5486(1) 3989(1) 70(1) 
O(3) -698(2) 3105(1) 1223(1) 55(1) 
O(4) -3857(3) 4633(2) 1630(1) 86(1) 
O(5) 2570(2) 840(1) 2782(1) 52(1) 
O(6) -1031(2) 1244(1) 3386(1) 68(1) 
C(1) -2486(3) 4852(2) 3365(2) 57(1) 
C(2) 832(3) 4921(2) 3792(1) 51(1) 
C(3) 1215(3) 3425(2) 3856(1) 45(1) 
C(4) 744(2) 3061(1) 2884(1) 40(1) 
C(5) -2121(3) 3949(2) 1807(1) 54(1) 
C(6) -1270(3) 2775(2) 317(1) 58(1) 
C(7) -1654(6) 3991(3) -460(2) 94(1) 
C(8) -3220(5) 2171(3) 633(2) 99(1) 
C(9) 767(5) 1781(3) -57(2) 93(1) 
C(10) 613(2) 1605(2) 3047(1) 41(1) 
C(11) 3021(3) -637(2) 2982(1) 58(1) 
C(12) 2387(5) -1094(2) 4080(2) 90(1) 
C(13) 5491(5) -1004(3) 2714(4) 151(2) 
C(14) 1878(8) -1131(3) 2347(3) 128(1) 




 Table 3.   Bond lengths [Å] and angles [°] for  7468. 
_____________________________________________________  
N(1)-C(5)  1.365(2) 
N(1)-C(1)  1.431(2) 
N(1)-C(4)  1.4591(18) 
O(1)-C(2)  1.345(2) 
O(1)-C(1)  1.440(2) 
O(2)-C(2)  1.196(2) 
O(3)-C(5)  1.332(2) 
O(3)-C(6)  1.4777(19) 
O(4)-C(5)  1.204(2) 
O(5)-C(10)  1.3199(18) 
O(5)-C(11)  1.4862(19) 
O(6)-C(10)  1.1910(19) 
C(2)-C(3)  1.513(2) 
C(3)-C(15)  1.513(2) 
C(3)-C(4)  1.548(2) 
C(4)-C(10)  1.527(2) 
C(6)-C(8)  1.501(3) 
C(6)-C(9)  1.502(3) 
C(6)-C(7)  1.507(3) 
C(11)-C(14)  1.477(4) 
C(11)-C(12)  1.491(3) 











































 Table 4.   Anisotropic displacement parameters  (Å2x 103) for 7468.  The anisotropic 
displacement factor exponent takes the form:  -2pi2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N(1) 52(1)  41(1) 48(1)  -12(1) -16(1)  5(1) 
O(1) 72(1)  40(1) 78(1)  -20(1) -21(1)  -1(1) 
O(2) 77(1)  61(1) 83(1)  -26(1) -11(1)  -26(1) 
O(3) 66(1)  56(1) 43(1)  -12(1) -20(1)  -2(1) 
O(4) 81(1)  89(1) 84(1)  -29(1) -47(1)  26(1) 
O(5) 50(1)  34(1) 63(1)  -7(1) -1(1)  -2(1) 
O(6) 48(1)  51(1) 100(1)  -5(1) -4(1)  -12(1) 
C(1) 53(1)  50(1) 67(1)  -24(1) -16(1)  5(1) 
C(2) 60(1)  45(1) 48(1)  -16(1) -5(1)  -13(1) 
C(3) 51(1)  42(1) 43(1)  -10(1) -11(1)  -8(1) 
C(4) 44(1)  36(1) 38(1)  -7(1) -8(1)  -3(1) 
C(5) 62(1)  48(1) 51(1)  -7(1) -21(1)  0(1) 
C(6) 74(1)  63(1) 44(1)  -10(1) -19(1)  -18(1) 
C(7) 144(2)  93(2) 57(1)  7(1) -45(1)  -36(2) 
C(8) 112(2)  124(2) 84(2)  -33(2) -5(2)  -64(2) 
C(9) 101(2)  110(2) 69(1)  -44(1) -22(1)  1(2) 
C(10) 45(1)  39(1) 39(1)  -7(1) -10(1)  -5(1) 
C(11) 70(1)  32(1) 63(1)  -6(1) -3(1)  -1(1) 
C(12) 138(2)  53(1) 68(1)  6(1) -30(1)  -5(1) 
C(13) 89(2)  54(1) 251(5)  1(2) 41(2)  17(1) 
C(14) 242(4)  50(1) 115(2)  -20(1) -95(3)  -15(2) 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 20:25:03
DATE_d : Apr 09 2008
NS :            669
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
*** Processing Parameters ***
SF :     75.4677508 MHz
XDIM :             64
*** 1D NMR Plot Parameters ***
Start :         224.14 ppm
Stop :         -14.18 ppm
YScale :         100.00 %
SR :           1.80 Hz





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































NAME            skg1022
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20101022
Time              13.36
INSTRUM           spect
PROBHD   5 mm TXI 1H-13
PULPROG          cosygs
TD                 2048
SOLVENT            C6D6
NS                   16
DS                    8
SWH            3822.630 Hz
FIDRES         1.866518 Hz
AQ            0.2680592 sec
RG                  181
DW              130.800 usec
DE                 6.00 usec
TE                298.0 K
D0           0.00000300 sec
D1           1.00000000 sec
D13          0.00000300 sec
D16          0.00020000 sec
IN0          0.00026160 sec
======== CHANNEL f1 ========
NUC1                 1H
P0                 8.20 usec
P1                 8.20 usec
PL1               -2.00 dB
SFO1        500.2320434 MHz
====== GRADIENT CHANNEL =====
P16             1500.00 usec
F1 - Acquisition parameters
ND0                   1
TD                  512
SFO1            500.232 MHz
FIDRES         7.466074 Hz
SW                7.642 ppm
FnMODE               QF
F2 - Processing parameters
SI                  512
SF          500.2300053 MHz
WDW                SINE
SSB                   0
LB                 0.00 Hz
GB                    0
PC                 1.40
F1 - Processing parameters
SI                  512
MC2                  QF
SF          500.2300062 MHz
WDW                SINE
SSB                   0
LB                 0.00 Hz


















































NAME            skg1022
EXPNO                12
PROCNO                1
F2 - Acquisition Parameters
Date_          20101022
Time              21.19
INSTRUM           spect
PROBHD   5 mm TXI 1H-13
PULPROG        inv4gstp
TD                  512
SOLVENT            MeOH
NS                   16
DS                    6
SWH            3894.081 Hz
FIDRES         7.605627 Hz
AQ            0.0659192 sec
RG                  128
DW              128.400 usec
DE                 6.00 usec
TE                298.1 K
D0           0.00000300 sec
D1           1.00000000 sec
D2           0.00345000 sec
d4           0.00172500 sec
D11          0.03000000 sec
D13          0.00000300 sec
D16          0.00020000 sec
d20          0.00002500 sec
d21          0.00174600 sec
IN0          0.00000946 sec
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.20 usec
P2                16.40 usec
PL1               -2.00 dB
SFO1        500.2320981 MHz
======== CHANNEL f2 ========
CPDPRG2            garp
NUC2                13C
P3                13.20 usec
P4                26.40 usec
PCPD2             70.00 usec
PL2               -2.00 dB
PL12              12.49 dB
SFO2        125.7942545 MHz
====== GRADIENT CHANNEL =====
P16             1500.00 usec
F1 - Acquisition parameters
ND0                   4
TD                  512
SFO1           125.7943 MHz
FIDRES        51.601719 Hz
SW              210.026 ppm
FnMODE             TPPI
F2 - Processing parameters
SI                  512
SF          500.2300083 MHz
WDW               QSINE
SSB                   2
LB                 0.00 Hz
GB                    0
PC                 1.40
F1 - Processing parameters
SI                  512
MC2                TPPI
SF          125.7829116 MHz
WDW               QSINE
SSB                   2
LB                 0.00 Hz














































0 Current Data ParametersNAME            skg1022EXPNO                13
PROCNO                1
F2 - Acquisition Parameters
Date_          20101022
Time              23.49
INSTRUM           spect
PROBHD   5 mm TXI 1H-13
PULPROG    inv4gplplrnd
TD                 2048
SOLVENT           CDCl3
NS                   32
DS                    8
SWH            3894.081 Hz
FIDRES         1.901407 Hz
AQ            0.2631416 sec
RG                 8192
DW              128.400 usec
DE                 6.00 usec
TE                298.4 K
D0           0.00000300 sec
D1           2.00000000 sec
D2           0.00345000 sec
D6           0.10000000 sec
D13          0.00000300 sec
D16          0.00020000 sec
IN0          0.00001728 sec
======== CHANNEL f1 ========
NUC1                 1H
P1                 8.20 usec
P2                16.40 usec
PL1               -2.00 dB
SFO1        500.2320981 MHz
======== CHANNEL f2 ========
NUC2                13C
P3                13.20 usec
PL2               -2.00 dB
SFO2        125.7967701 MHz
====== GRADIENT CHANNEL =====
GPNAM1         sine.100
GPNAM2         sine.100
GPNAM3         sine.100
GPX1               0.00 %
GPX2               0.00 %
GPX3               0.00 %
GPY1               0.00 %
GPY2               0.00 %
GPY3               0.00 %
GPZ1              50.00 %
GPZ2              30.00 %
GPZ3              40.00 %
P16             1500.00 usec
F1 - Acquisition parameters
ND0                   2
TD                  512
SFO1           125.7968 MHz
FIDRES        56.530392 Hz
SW              230.082 ppm
FnMODE               QF
F2 - Processing parameters
SI                 2048
SF          500.2300083 MHz
WDW               QSINE
SSB                   0
LB                 0.00 Hz
GB                    0
PC                 1.40
F1 - Processing parameters
SI                  512
MC2                  QF
SF          125.7828890 MHz
WDW                SINE
SSB                   0
LB                 0.00 Hz
GB                    0
SG0487
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